BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-131. [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038] [Cited by in Crossref: 1312] [Cited by in F6Publishing: 1141] [Article Influence: 119.3] [Reference Citation Analysis]
Number Citing Articles
1 Kitson MT, Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol. 2012;57:897-909. [PMID: 22634121 DOI: 10.1016/j.jhep.2012.04.033] [Cited by in Crossref: 134] [Cited by in F6Publishing: 110] [Article Influence: 14.9] [Reference Citation Analysis]
2 Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43:83-95. [PMID: 26369383 DOI: 10.1111/apt.13405] [Cited by in Crossref: 109] [Cited by in F6Publishing: 82] [Article Influence: 18.2] [Reference Citation Analysis]
3 Borém LMA, Neto JFR, Brandi IV, Lelis DF, Santos SHS. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertens Res 2018;41:394-405. [PMID: 29636553 DOI: 10.1038/s41440-018-0040-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
4 He X, Wang L, Gu X, Xiao J, Qiu W. A facile synthesis of ursodeoxycholic acid and obeticholic acid from cholic acid. Steroids 2018;140:173-8. [DOI: 10.1016/j.steroids.2018.10.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Silaghi CA, Silaghi H, Colosi HA, Craciun AE, Farcas A, Cosma DT, Hancu N, Pais R, Georgescu CE. Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population. Clujul Med 2016;89:82-8. [PMID: 27004029 DOI: 10.15386/cjmed-544] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
6 Hoodeshenas S, Yin M, Venkatesh SK. Magnetic Resonance Elastography of Liver: Current Update. Top Magn Reson Imaging. 2018;27:319-333. [PMID: 30289828 DOI: 10.1097/rmr.0000000000000177] [Cited by in Crossref: 39] [Cited by in F6Publishing: 9] [Article Influence: 19.5] [Reference Citation Analysis]
7 Alexander J, Torbenson M, Wu TT, Yeh MM. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol. 2013;28:848-854. [PMID: 23302015 DOI: 10.1111/jgh.12116] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 9.6] [Reference Citation Analysis]
8 [DOI: 10.1101/523217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Alswat K, Aljumah AA, Sanai FM, Abaalkhail F, Alghamdi M, Al Hamoudi WK, Al Khathlan A, Al Quraishi H, Al Rifai A, Al Zaabi M, Babatin MA, Estes C, Hashim A, Razavi H. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. Saudi J Gastroenterol. 2018;24:211-219. [PMID: 29956688 DOI: 10.4103/sjg.sjg_122_18] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
10 Hajifathalian K, Mehta A, Ang B, Skaf D, Shah SL, Saumoy M, Dawod Q, Dawod E, Shukla A, Aronne L, Brown RS, Cohen DE, Dannenberg AJ, Fortune B, Kumar S, Sharaiha RZ. Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. Gastrointest Endosc 2021;93:1110-8. [PMID: 32861753 DOI: 10.1016/j.gie.2020.08.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
11 Mahady SE, George J. Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism 2016;65:1172-82. [DOI: 10.1016/j.metabol.2015.10.032] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
12 Verdam FJ, Dallinga JW, Driessen A, de Jonge C, Moonen EJ, van Berkel JB, Luijk J, Bouvy ND, Buurman WA, Rensen SS, Greve JW, van Schooten FJ. Non-alcoholic steatohepatitis: A non-invasive diagnosis by analysis of exhaled breath. J Hepatol. 2013;58:543-548. [PMID: 23142062 DOI: 10.1016/j.jhep.2012.10.030] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
13 Illnait J, Rodríguez I, Mendoza S, Fernández Y, Mas R, Miranda M, Piñera J, Fernández JC, Mesa M, Fernández L, Carbajal D, Gámez R. Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease. Korean J Intern Med 2013;28:439-48. [PMID: 23864802 DOI: 10.3904/kjim.2013.28.4.439] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
14 Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-gomez M, Zelber-sagi S, Wai-sun Wong V, Dufour J, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-järvinen H, Fan J, Grønbæk H, Yilmaz Y, Cortez-pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng M, Fouad Y, Chan W, Mendez-sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology 2020;73:202-9. [DOI: 10.1016/j.jhep.2020.03.039] [Cited by in Crossref: 390] [Cited by in F6Publishing: 326] [Article Influence: 390.0] [Reference Citation Analysis]
15 Polyzos SA, Kountouras J, Mantzoros CS. Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease. Metabolism 2012;61:755-8. [PMID: 22386938 DOI: 10.1016/j.metabol.2012.01.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
16 Calzada E, Onguka O, Claypool SM. Phosphatidylethanolamine Metabolism in Health and Disease. Int Rev Cell Mol Biol 2016;321:29-88. [PMID: 26811286 DOI: 10.1016/bs.ircmb.2015.10.001] [Cited by in Crossref: 95] [Cited by in F6Publishing: 74] [Article Influence: 15.8] [Reference Citation Analysis]
17 Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, Madsen KL, Reimer RA. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol 2015;15:169. [PMID: 26635079 DOI: 10.1186/s12876-015-0400-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
18 Mei L, Tang Y, Li M, Yang P, Liu Z, Yuan J, Zheng P. Co-Administration of Cholesterol-Lowering Probiotics and Anthraquinone from Cassia obtusifolia L. Ameliorate Non-Alcoholic Fatty Liver. PLoS One 2015;10:e0138078. [PMID: 26375281 DOI: 10.1371/journal.pone.0138078] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
19 Chou YT, Li CH, Sun ZJ, Shen WC, Yang YC, Lu FH, Chang CJ, Wu JS. A Positive Relationship between Betel Nut Chewing and Significant Liver Fibrosis in NAFLD Subjects, but Not in Non-NAFLD Ones. Nutrients 2021;13:914. [PMID: 33799865 DOI: 10.3390/nu13030914] [Reference Citation Analysis]
20 Pimentel CF, Jiang ZG, Otsubo T, Feldbrügge L, Challies TL, Nasser I, Robson S, Afdhal N, Lai M. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci 2016;61:905-12. [PMID: 26462489 DOI: 10.1007/s10620-015-3916-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
21 Tien PC. Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy. Curr Atheroscler Rep 2015;17:73. [PMID: 26493063 DOI: 10.1007/s11883-015-0545-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Ofosu A, Ramai D, Reddy M. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann Gastroenterol. 2018;31:288-295. [PMID: 29720854 DOI: 10.20524/aog.2018.0240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
23 Robinson A, Ohri A, Liu B, Bhuket T, Wong RJ. One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation. World J Hepatol 2018;10:956-65. [PMID: 30631400 DOI: 10.4254/wjh.v10.i12.956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhang B, Ding F, Chen T, Xia LH, Qian J, Lv GY. Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content. World J Gastroenterol. 2014;20:17985-17992. [PMID: 25548498 DOI: 10.3748/wjg.v20.i47.17985] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
25 Margariti A, Kontogianni MD, Tileli N, Georgoulis M, Deutsch M, Zafeiropoulou R, Tiniakos D, Manios Y, Pectasides D, Papatheodoridis GV. Increased abdominal fat levels measured by bioelectrical impedance are associated with histological lesions of nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2015;27:907-13. [PMID: 26011231 DOI: 10.1097/MEG.0000000000000381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
26 De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM, Foster GR, Syn WK, Alazawi W. Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. Frontline Gastroenterol 2018;9:115-21. [PMID: 29588839 DOI: 10.1136/flgastro-2017-100865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
27 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
28 Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014;6:274-283. [PMID: 24868321 DOI: 10.4254/wjh.v6.i5.274] [Cited by in Crossref: 154] [Cited by in F6Publishing: 127] [Article Influence: 22.0] [Reference Citation Analysis]
29 Khurana S, Butt W, Khara HS, Johal AS, West SF, Chen ZE, Berger AL, Diehl DL. Bi-lobar liver biopsy via EUS enhances the assessment of disease severity in patients with non-alcoholic steatohepatitis. Hepatol Int 2019;13:323-9. [DOI: 10.1007/s12072-019-09945-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
30 Vilar-Gomez E, Lou Z, Kong N, Vuppalanchi R, Imperiale TF, Chalasani N. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System. Clin Gastroenterol Hepatol 2020;18:2305-2314.e12. [PMID: 32289535 DOI: 10.1016/j.cgh.2020.04.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
31 Tarry-Adkins JL, Fernandez-Twinn DS, Hargreaves IP, Neergheen V, Aiken CE, Martin-Gronert MS, McConnell JM, Ozanne SE. Coenzyme Q10 prevents hepatic fibrosis, inflammation, and oxidative stress in a male rat model of poor maternal nutrition and accelerated postnatal growth. Am J Clin Nutr 2016;103:579-88. [PMID: 26718412 DOI: 10.3945/ajcn.115.119834] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
32 Yarrington CD, Cantonwine DE, Seely EW, Mcelrath TF, Zera CA. The Association of Alanine Aminotransferase in Early Pregnancy with Gestational Diabetes. Metabolic Syndrome and Related Disorders 2016;14:254-8. [DOI: 10.1089/met.2015.0106] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
33 Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients 2017;9:E387. [PMID: 28420094 DOI: 10.3390/nu9040387] [Cited by in Crossref: 166] [Cited by in F6Publishing: 122] [Article Influence: 41.5] [Reference Citation Analysis]
34 Baciu C, Pasini E, Angeli M, Schwenger K, Afrin J, Humar A, Fischer S, Patel K, Allard J, Bhat M. Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis. PLoS One 2017;12:e0189223. [PMID: 29216278 DOI: 10.1371/journal.pone.0189223] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
35 Moosburner S, Gassner JMGV, Nösser M, Pohl J, Wyrwal D, Claussen F, Ritschl PV, Dragun D, Pratschke J, Sauer IM, Raschzok N. Prevalence of Steatosis Hepatis in the Eurotransplant Region: Impact on Graft Acceptance Rates. HPB Surg 2018;2018:6094936. [PMID: 30515073 DOI: 10.1155/2018/6094936] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
36 Farrell GC, van Rooyen D. Liver cholesterol: is it playing possum in NASH? Am J Physiol Gastrointest Liver Physiol. 2012;303:G9-11. [PMID: 22556144 DOI: 10.1152/ajpgi.00008.2012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
37 Torres DM, Harrison SA. Noninvasive methods of assessing nonalcoholic fatty liver disease: what the clinician needs to know. Clin Gastroenterol Hepatol. 2013;11:1205-1207. [PMID: 23811242 DOI: 10.1016/j.cgh.2013.05.040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
38 Pinon-Gutierrez R, Durbin-Johnson B, Halsted CH, Medici V. Clinical features of alcoholic hepatitis in latinos and caucasians: A single center experience. World J Gastroenterol 2017;23:7274-82. [PMID: 29142474 DOI: 10.3748/wjg.v23.i40.7274] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Chen VL, Wright AP, Halligan B, Chen Y, Du X, Handelman SK, Long MT, Kiel DP, Speliotes EK. Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis. Hepatol Commun 2019;3:1073-84. [PMID: 31388628 DOI: 10.1002/hep4.1391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
40 Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism 2020;111S:154183. [PMID: 32061907 DOI: 10.1016/j.metabol.2020.154183] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
41 Szanto KB, Li J, Cordero P, Oben JA. Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019;12:357-367. [PMID: 30936733 DOI: 10.2147/dmso.s182331] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
42 Teratani T, Tomita K, Suzuki T, Furuhashi H, Irie R, Nishikawa M, Yamamoto J, Hibi T, Miura S, Minamino T, Oike Y, Hokari R, Kanai T. Aortic carboxypeptidase-like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis. J Clin Invest 2018;128:1581-96. [PMID: 29553485 DOI: 10.1172/JCI92863] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
43 Zhang QQ, Lu LG. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol 2015;3:78-84. [PMID: 26357637 DOI: 10.14218/JCTH.2014.00037] [Cited by in Crossref: 41] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
44 Cremonini E, Wang Z, Bettaieb A, Adamo AM, Daveri E, Mills DA, Kalanetra KM, Haj FG, Karakas S, Oteiza PI. (-)-Epicatechin protects the intestinal barrier from high fat diet-induced permeabilization: Implications for steatosis and insulin resistance. Redox Biol 2018;14:588-99. [PMID: 29154190 DOI: 10.1016/j.redox.2017.11.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 14.5] [Reference Citation Analysis]
45 Kim HS, El-Serag HB. The Epidemiology of Hepatocellular Carcinoma in the USA. Curr Gastroenterol Rep. 2019;21:17. [PMID: 30976932 DOI: 10.1007/s11894-019-0681-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 18.5] [Reference Citation Analysis]
46 Yilmaz B, Sahin K, Bilen H, Bahcecioglu IH, Bilir B, Ashraf S, Halazun KJ, Kucuk O. Carotenoids and non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2015;4:161-171. [PMID: 26151056 DOI: 10.3978/j.issn.2304-3881.2015.01.11] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
47 de Lédinghen V, Hiriart J, Vergniol J, Merrouche W, Bedossa P, Paradis V. Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy. Dig Dis Sci 2017;62:2569-77. [DOI: 10.1007/s10620-017-4638-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 12.8] [Reference Citation Analysis]
48 Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A, Hernandez C, Nguyen P, Aryafar H, Valasek M, Haufe W, Hooker C, Richards L, Sirlin CB, Loomba R. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2016;9:692-701. [PMID: 27582882 DOI: 10.1177/1756283X16656735] [Cited by in Crossref: 80] [Cited by in F6Publishing: 34] [Article Influence: 16.0] [Reference Citation Analysis]
49 Inoue M, Hayashi A, Taguchi T, Arai R, Sasaki S, Takano K, Inoue Y, Shichiri M. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. J Diabetes Investig 2019;10:1004-11. [PMID: 30461221 DOI: 10.1111/jdi.12980] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 20.0] [Reference Citation Analysis]
50 Chheda TK, Shivakumar P, Sadasivan SK, Chanderasekharan H, Moolemath Y, Oommen AM, Madanahalli JR, Marikunte VV. Fast food diet with CCl4 micro-dose induced hepatic-fibrosis--a novel animal model. BMC Gastroenterol. 2014;14:89. [PMID: 24884574 DOI: 10.1186/1471-230x-14-89] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
51 Wei Z, Ren Z, Hu S, Gao Y, Sun R, Lv S, Yang G, Yu Z, Kan Q. Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease. Cancer Med 2020;9:1254-62. [PMID: 31860170 DOI: 10.1002/cam4.2777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
52 Lee DH. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2020;35:243-59. [PMID: 32615709 DOI: 10.3803/EnM.2020.35.2.243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
53 Goceri E, Shah ZK, Layman R, Jiang X, Gurcan MN. Quantification of liver fat: A comprehensive review. Comput Biol Med 2016;71:174-89. [PMID: 26945465 DOI: 10.1016/j.compbiomed.2016.02.013] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 7.4] [Reference Citation Analysis]
54 Régnier M, Polizzi A, Guillou H, Loiseau N. Sphingolipid metabolism in non-alcoholic fatty liver diseases. Biochimie 2019;159:9-22. [PMID: 30071259 DOI: 10.1016/j.biochi.2018.07.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
55 Rinella ME. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology 2011;54:1118-20. [DOI: 10.1002/hep.24634] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
56 Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. Liver Transpl 2018;24:1171-7. [PMID: 29781162 DOI: 10.1002/lt.25202] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
57 Ahmed IA, Mikail MA, Ibrahim M. Baccaurea angulata fruit juice ameliorates altered hematological and biochemical biomarkers in diet-induced hypercholesterolemic rabbits. Nutr Res 2017;42:31-42. [PMID: 28633869 DOI: 10.1016/j.nutres.2017.04.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
58 Kennedy L, Meadows V, Sybenga A, Demieville J, Chen L, Hargrove L, Ekser B, Dar W, Ceci L, Kundu D, Kyritsi K, Pham L, Zhou T, Glaser S, Meng F, Alpini G, Francis H. Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet. Hepatology 2021;74:164-82. [PMID: 33434322 DOI: 10.1002/hep.31713] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Li Z, Xue J, Chen P, Chen L, Yan S, Liu L. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol. 2014;29:42-51. [PMID: 24219010 DOI: 10.1111/jgh.12428] [Cited by in Crossref: 125] [Cited by in F6Publishing: 111] [Article Influence: 17.9] [Reference Citation Analysis]
60 Su H, Liu D, Shao J, Li Y, Wang X, Gao Q. Aging Liver: Can Exercise be a Better Way to Delay the Process than Nutritional and Pharmacological Intervention? Focus on Lipid Metabolism. Curr Pharm Des 2020;26:4982-91. [PMID: 32503400 DOI: 10.2174/1381612826666200605111232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Shetty A, Cho W, Alazawi W, Syn WK. Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease. Am J Med Sci 2017;354:172-81. [PMID: 28864376 DOI: 10.1016/j.amjms.2017.03.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
62 Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
63 Gómez-Hurtado I, Gallego-Durán R, Zapater P, Ampuero J, Aller R, Crespo J, Arias-Loste M, García-Monzón C, Bellot P, González-Rodríguez Á, Juanola O, Romero-Gómez M, Francés R. Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. Liver Int 2020;40:2182-93. [PMID: 32559006 DOI: 10.1111/liv.14571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
64 Tsuneyama K, Baba H, Kikuchi K, Nishida T, Nomoto K, Hayashi S, Miwa S, Nakajima T, Nakanishi Y, Masuda S. Autoimmune features in metabolic liver disease: a single-center experience and review of the literature. Clin Rev Allergy Immunol. 2013;45:143-148. [PMID: 23842720 DOI: 10.1007/s12016-013-8383-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
65 Hanson A, Wilhelmsen D, DiStefano JK. The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD). Noncoding RNA 2018;4:E18. [PMID: 30134610 DOI: 10.3390/ncrna4030018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
66 Sharma P, Arora A. Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis. Transl Gastroenterol Hepatol 2020;5:19. [PMID: 32258523 DOI: 10.21037/tgh.2019.10.02] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
67 Jiang W, Huang S, Teng H, Wang P, Wu M, Zhou X, Ran H. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open 2018;8:e021787. [PMID: 30139901 DOI: 10.1136/bmjopen-2018-021787] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 12.7] [Reference Citation Analysis]
68 Gerstenmaier JF, Gibson RN. Ultrasound in chronic liver disease. Insights Imaging 2014;5:441-55. [PMID: 24859758 DOI: 10.1007/s13244-014-0336-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 6.9] [Reference Citation Analysis]
69 Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 2016;8:45. [PMID: 27462372 DOI: 10.1186/s13098-016-0169-x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 19.2] [Reference Citation Analysis]
70 Povero D, Eguchi A, Li H, Johnson CD, Papouchado BG, Wree A, Messer K, Feldstein AE. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One 2014;9:e113651. [PMID: 25470250 DOI: 10.1371/journal.pone.0113651] [Cited by in Crossref: 152] [Cited by in F6Publishing: 140] [Article Influence: 21.7] [Reference Citation Analysis]
71 Wahi G, Anand SS. Race/Ethnicity, Obesity, and Related Cardio-Metabolic Risk Factors: A Life-Course Perspective. Curr Cardiovasc Risk Rep 2013;7:326-35. [PMID: 24672590 DOI: 10.1007/s12170-013-0329-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
72 Keskin M, Hayıroğlu Mİ, Uzun AO, Güvenç TS, Şahin S, Kozan Ö. Effect of Nonalcoholic Fatty Liver Disease on In-Hospital and Long-Term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction. Am J Cardiol 2017;120:1720-6. [PMID: 28867124 DOI: 10.1016/j.amjcard.2017.07.107] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
73 Botello-Manilla AE, López-Sánchez GN, Chávez-Tapia NC, Uribe M, Nuño-Lámbarri N. Hepatic steatosis and respiratory diseases: a new panorama. Ann Hepatol 2021;24:100320. [PMID: 33549735 DOI: 10.1016/j.aohep.2021.100320] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Roy S, Ghosh A. Significant Reduction of Elevated Triglycerides and Liver Fibrosis in Diabetic Dyslipidemia with Saroglitazar: A Case Report. Cureus 2019;11:e6361. [PMID: 31886093 DOI: 10.7759/cureus.6361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Wu G, Niu M, Tang W, Hu J, Wei G, He Z, Chen Y, Jiang Y, Chen P. L-Fucose ameliorates high-fat diet-induced obesity and hepatic steatosis in mice. J Transl Med 2018;16:344. [PMID: 30526624 DOI: 10.1186/s12967-018-1718-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
76 Konstantakis C, Tselekouni P, Kalafateli M, Triantos C. Vitamin D deficiency in patients with liver cirrhosis. Ann Gastroenterol. 2016;29:297-306. [PMID: 27366029 DOI: 10.20524/aog.2016.0037] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
77 Shen H, Lipka S, Kumar A, Mustacchia P. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systemic review and meta-analysis. J Gastrointest Oncol. 2014;5:440-446. [PMID: 25436123 DOI: 10.3978/j.issn.2078-6891.2014.061] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
78 Selby LV, Ejaz A, Brethauer SA, Pawlik TM. Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery. Expert Opin Investig Drugs 2020;29:107-10. [PMID: 31986920 DOI: 10.1080/13543784.2020.1721457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Kohli R, Feldstein AE. NASH animal models: are we there yet? J Hepatol 2011;55:941-3. [PMID: 21708199 DOI: 10.1016/j.jhep.2011.04.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
80 Sonmez A, Nikolic D, Dogru T, Ercin CN, Genc H, Cesur M, Tapan S, Karslioğlu Y, Montalto G, Banach M, Toth PP, Bagci S, Rizzo M. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. J Clin Lipidol 2015;9:576-82. [PMID: 26228676 DOI: 10.1016/j.jacl.2015.03.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
81 Mansour-Ghanaei R, Mansour-Ghanaei F, Naghipour M, Joukar F, Atrkar-Roushan Z, Tabatabaii M, Ghorani N. The role of anthropometric indices in the prediction of non-alcoholic fatty liver disease in the PERSIAN Guilan Cohort study (PGCS). J Med Life 2018;11:194-202. [PMID: 30364682 DOI: 10.25122/jml-2018-0031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
82 Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. J Clin Endocrinol Metab. 2015;100:2231-2238. [PMID: 25885947 DOI: 10.1210/jc.2015-1966] [Cited by in Crossref: 238] [Cited by in F6Publishing: 191] [Article Influence: 39.7] [Reference Citation Analysis]
83 De Luca-Johnson J, Wangensteen KJ, Hanson J, Krawitt E, Wilcox R. Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016;61:2710-20. [PMID: 27262844 DOI: 10.1007/s10620-016-4213-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
84 Lyall MJ, Cartier J, Thomson JP, Cameron K, Meseguer-Ripolles J, O'Duibhir E, Szkolnicka D, Villarin BL, Wang Y, Blanco GR, Dunn WB, Meehan RR, Hay DC, Drake AJ. Modelling non-alcoholic fatty liver disease in human hepatocyte-like cells. Philos Trans R Soc Lond B Biol Sci 2018;373:20170362. [PMID: 29786565 DOI: 10.1098/rstb.2017.0362] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
85 Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, Havekes LM, Kleemann R, van den Hoek AM. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One 2014;9:e115922. [PMID: 25535951 DOI: 10.1371/journal.pone.0115922] [Cited by in Crossref: 183] [Cited by in F6Publishing: 157] [Article Influence: 26.1] [Reference Citation Analysis]
86 Kyriakides M, Hardwick RN, Jin Z, Goedken MJ, Holmes E, Cherrington NJ, Coen M. Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat. Toxicol Sci 2014;142:105-16. [PMID: 25145655 DOI: 10.1093/toxsci/kfu160] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
87 Acharya UR, Fujita H, Sudarshan VK, Mookiah MRK, Koh JE, Tan JH, Hagiwara Y, Chua CK, Junnarkar SP, Vijayananthan A, Ng KH. An integrated index for identification of fatty liver disease using radon transform and discrete cosine transform features in ultrasound images. Information Fusion 2016;31:43-53. [DOI: 10.1016/j.inffus.2015.12.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 6.2] [Reference Citation Analysis]
88 Alkhouri N, Hanouneh IA, Zein NN, Lopez R, Kelly D, Eghtesad B, Fung JJ. Liver transplantation for nonalcoholic steatohepatitis in young patients. Transpl Int. 2016;29:418-424. [PMID: 26402655 DOI: 10.1111/tri.12694] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
89 Carruthers JE, Bottle A, Laverty AA, Khan SA, Millett C, Vamos EP. Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England. Diabetes Res Clin Pract 2017;132:102-7. [PMID: 28829976 DOI: 10.1016/j.diabres.2017.07.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
90 Umetsu S, Mizukami H, Saito T, Uchida C, Igawa A, Kudo K, Itabashi C, Osonoi S, Danyang G, Sasaki T, Yagihashi S, Hakamada K. Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation. Sci Rep 2020;10:1156. [PMID: 31980687 DOI: 10.1038/s41598-020-57883-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Glassner K, Malaty HM, Abraham BP. Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:998-1003. [DOI: 10.1097/mib.0000000000001085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
92 Weinstein G, Davis-Plourde K, Himali JJ, Zelber-Sagi S, Beiser AS, Seshadri S. Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study. Liver Int 2019;39:1713-21. [PMID: 31155826 DOI: 10.1111/liv.14161] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
93 Garcia-Carretero R, Vigil-Medina L, Barquero-Perez O, Ramos-Lopez J. Relevant Features in Nonalcoholic Steatohepatitis Determined Using Machine Learning for Feature Selection. Metab Syndr Relat Disord 2019;17:444-51. [PMID: 31675274 DOI: 10.1089/met.2019.0052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
94 Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33:1398-1405. [PMID: 23763360 DOI: 10.1111/liv.12226] [Cited by in Crossref: 143] [Cited by in F6Publishing: 123] [Article Influence: 17.9] [Reference Citation Analysis]
95 Dogan Z, Filik L, Ergül B, Sarikaya M. Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis. Saudi J Gastroenterol 2015;21:396-9. [PMID: 26655136 DOI: 10.4103/1319-3767.164186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
96 Takyar V, Nath A, Beri A, Gharib AM, Rotman Y. How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool. Hepatology 2017;66:825-33. [PMID: 28470683 DOI: 10.1002/hep.29247] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
97 Chiang H, Lee JC, Huang HC, Huang H, Liu HK, Huang C. Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice. Br J Pharmacol 2020;177:239-53. [PMID: 31497874 DOI: 10.1111/bph.14859] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
98 Tokodai K, Karadagi A, Kjaernet F, Romano A, Ericzon BG, Nowak G. Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation. Scand J Gastroenterol 2019;54:233-9. [PMID: 30999770 DOI: 10.1080/00365521.2019.1577484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
99 Liu PY, Chen CC, Chin CY, Liu TJ, Tsai WC, Chou JL, Huang CY, Chen YG, Chen YC. E3 ubiquitin ligase Grail promotes hepatic steatosis through Sirt1 inhibition. Cell Death Dis 2021;12:323. [PMID: 33771967 DOI: 10.1038/s41419-021-03608-9] [Reference Citation Analysis]
100 Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Clinical characteristics and longitudinal changes of patients with non-alcoholic fatty liver disease in 2 decades: the NAGALA study. BMC Gastroenterol 2021;21:223. [PMID: 34001028 DOI: 10.1186/s12876-021-01809-2] [Reference Citation Analysis]
101 Hetterich H, Bayerl C, Peters A, Heier M, Linkohr B, Meisinger C, Auweter S, Kannengießer SA, Kramer H, Ertl-Wagner B, Bamberg F. Feasibility of a three-step magnetic resonance imaging approach for the assessment of hepatic steatosis in an asymptomatic study population. Eur Radiol 2016;26:1895-904. [PMID: 26340812 DOI: 10.1007/s00330-015-3966-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
102 McGettigan B, McMahan R, Orlicky D, Burchill M, Danhorn T, Francis P, Cheng LL, Golden-Mason L, Jakubzick CV, Rosen HR. Dietary Lipids Differentially Shape Nonalcoholic Steatohepatitis Progression and the Transcriptome of Kupffer Cells and Infiltrating Macrophages. Hepatology. 2019;70:67-83. [PMID: 30516830 DOI: 10.1002/hep.30401] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 18.0] [Reference Citation Analysis]
103 Walenbergh SM, Koek GH, Bieghs V, Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol. 2013;58:801-810. [PMID: 23183522 DOI: 10.1016/j.jhep.2012.11.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
104 Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, Shin H, Ryu S. Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study. Am J Gastroenterol. 2019;114:453-463. [PMID: 30353055 DOI: 10.1038/s41395-018-0283-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
105 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. [PMID: 22641309 DOI: 10.1038/ajg.2012.128] [Cited by in Crossref: 245] [Cited by in F6Publishing: 218] [Article Influence: 27.2] [Reference Citation Analysis]
106 Schmeltzer PA, Talwalkar JA. Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am. 2011;40:507-521. [PMID: 21893271 DOI: 10.1016/j.gtc.2011.06.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
107 Loomba R, Lim JK, Patton H, El-Serag HB. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020;158:1822-30. [PMID: 32006545 DOI: 10.1053/j.gastro.2019.12.053] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 49.0] [Reference Citation Analysis]
108 Parker R, Hodson J, Rowe IAC. Systematic review: Current evidence in non-alcoholic fatty liver disease lacks relevance to patients with advanced fibrosis. J Gastroenterol Hepatol 2017;32:950-6. [PMID: 27796056 DOI: 10.1111/jgh.13625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
109 Goulart AC, Oliveira IR, Alencar AP, Santos MS, Santos IS, Martines BM, Meireles DP, Martines JA, Misciagna G, Benseñor IM, Lotufo PA. Diagnostic accuracy of a noninvasive hepatic ultrasound score for non-alcoholic fatty liver disease (NAFLD) in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Sao Paulo Med J 2015;133:115-24. [PMID: 26018881 DOI: 10.1590/1516-3180.2014.9150812] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
110 Taliento AE, Dallio M, Federico A, Prati D, Valenti L. Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease. Int J Environ Res Public Health 2019;16:E2755. [PMID: 31375010 DOI: 10.3390/ijerph16152755] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
111 Mandelia C, Kabbany MN, Conjeevaram Selvakumar PK, Alkhouri N. The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease. Biomark Med 2018;12:265-73. [PMID: 29517271 DOI: 10.2217/bmm-2017-0038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
112 Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033] [Cited by in Crossref: 190] [Cited by in F6Publishing: 150] [Article Influence: 38.0] [Reference Citation Analysis]
113 Clarke JD, Cherrington NJ. Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. Pharmacol Ther 2015;151:99-106. [PMID: 25805597 DOI: 10.1016/j.pharmthera.2015.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
114 Fukui A, Kawabe N, Hashimoto S, Murao M, Nakano T, Shimazaki H, Kan T, Nakaoka K, Ohki M, Takagawa Y. Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:2749-2756. [PMID: 26644818 DOI: 10.4254/wjh.v7.i27.2749] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
115 Polimeni L, Del Ben M, Baratta F, Perri L, Albanese F, Pastori D, Violi F, Angelico F. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol. 2015;7:1325-1336. [PMID: 26052378 DOI: 10.4254/wjh.v7.i10.1325] [Cited by in Crossref: 96] [Cited by in F6Publishing: 85] [Article Influence: 16.0] [Reference Citation Analysis]
116 Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896-904. [PMID: 29886156 DOI: 10.1016/j.jhep.2018.05.036] [Cited by in Crossref: 381] [Cited by in F6Publishing: 311] [Article Influence: 127.0] [Reference Citation Analysis]
117 Heimbach J. Debate: A bridge too far--liver transplantation for nonalcoholic steatohepatitis will overwhelm the organ supply. Liver Transpl. 2014;20 Suppl 2:S32-S37. [PMID: 25155244 DOI: 10.1002/lt.23980] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
118 Otoni A, Antunes CMF, Tavares FF, Araújo DHQ, Pereira TA, Queiroz LC, Amâncio FF, Lambertucci JR. Thrombocytopenia as a marker of liver steatosis in a low-endemic area for schistosomiasis mansoni. Rev Assoc Med Bras (1992) 2017;63:532-7. [PMID: 28876430 DOI: 10.1590/1806-9282.63.06.532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
119 Panjeshahin A, Mollahosseini M, Panbehkar‐jouybari M, Kaviani M, Mirzavandi F, Hosseinzadeh M. Effects of garlic supplementation on liver enzymes: A systematic review and meta‐analysis of randomized controlled trials. Phytotherapy Research 2020;34:1947-55. [DOI: 10.1002/ptr.6659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
120 Hajiaghamohammadi AA, Ziaee A, Samimi R. The efficacy of licorice root extract in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial. Phytother Res 2012;26:1381-4. [PMID: 22308054 DOI: 10.1002/ptr.3728] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
121 Sheng L, Jena PK, Liu HX, Kalanetra KM, Gonzalez FJ, French SW, Krishnan VV, Mills DA, Wan YY. Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation. Sci Rep. 2017;7:1748. [PMID: 28496104 DOI: 10.1038/s41598-017-01576-9] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 15.0] [Reference Citation Analysis]
122 Farsi F, Mohammadshahi M, Alavinejad P, Rezazadeh A, Zarei M, Engali KA. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J Am Coll Nutr. 2016;35:346-353. [PMID: 26156412 DOI: 10.1080/07315724.2015.1021057] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
123 Samji NS, Verma R, Satapathy SK. Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective. J Clin Exp Hepatol 2019;9:497-505. [PMID: 31516266 DOI: 10.1016/j.jceh.2019.05.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
124 Chen J, Wu L, Yang G, Zhang C, Liu X, Sun X, Chen X, Wang N. The influence of PM2.5 exposure on non-alcoholic fatty liver disease. Life Sci 2021;270:119135. [PMID: 33513397 DOI: 10.1016/j.lfs.2021.119135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
125 Acharya C, Bajaj JS. Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46:155-169. [PMID: 28164848 DOI: 10.1016/j.gtc.2016.09.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
126 Song M, Schuschke DA, Zhou Z, Zhong W, Zhang J, Zhang X, Wang Y, McClain CJ. Kupffer cell depletion protects against the steatosis, but not the liver damage, induced by marginal-copper, high-fructose diet in male rats. Am J Physiol Gastrointest Liver Physiol 2015;308:G934-45. [PMID: 25813056 DOI: 10.1152/ajpgi.00285.2014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
127 Ferslew BC, Johnston CK, Tsakalozou E, Bridges AS, Paine MF, Jia W, Stewart PW, Barritt AS 4th, Brouwer KL. Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. Clin Pharmacol Ther 2015;97:419-27. [PMID: 25669174 DOI: 10.1002/cpt.66] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
128 Fleischman MW, Budoff M, Zeb I, Li D, Foster T. NAFLD prevalence differs among hispanic subgroups: the Multi-Ethnic Study of Atherosclerosis. World J Gastroenterol 2014;20:4987-93. [PMID: 24803810 DOI: 10.3748/wjg.v20.i17.4987] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
129 Ota T. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Adv Exp Med Biol 2021;1261:223-9. [PMID: 33783745 DOI: 10.1007/978-981-15-7360-6_20] [Reference Citation Analysis]
130 Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB, Geller DA, Tsung A. Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. Hepatology. 2012;56:2221-2230. [PMID: 22767263 DOI: 10.1002/hep.25935] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
131 Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis. 2014;18:59-71. [PMID: 24274865 DOI: 10.1016/j.cld.2013.09.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 7.8] [Reference Citation Analysis]
132 Lin SC, Heba E, Bettencourt R, Lin GY, Valasek MA, Lunde O, Hamilton G, Sirlin CB, Loomba R. Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging. Aliment Pharmacol Ther 2017;45:844-54. [PMID: 28116801 DOI: 10.1111/apt.13951] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
133 Torres DM, Harrison SA. NAFLD: Predictive value of ALT levels for NASH and advanced fibrosis. Nat Rev Gastroenterol Hepatol. 2013;10:510-511. [PMID: 23897284 DOI: 10.1038/nrgastro.2013.138] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
134 Tarapure S, Tubaki BR, Khot S. Elastographic liver evaluation of Katukyadi churna in the management of Non-Alcoholic Steatohepatitis (NASH) - A single arm clinical trial. J Ayurveda Integr Med 2021;12:136-42. [PMID: 33579578 DOI: 10.1016/j.jaim.2020.12.015] [Reference Citation Analysis]
135 Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, Valasek MA, Ix JH, Schnabl B, Sirlin CB, Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2015;13:1513-20.e1. [PMID: 25661453 DOI: 10.1016/j.cgh.2015.01.027] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 10.7] [Reference Citation Analysis]
136 Wei G, An P, Vaid KA, Nasser I, Huang P, Tan L, Zhao S, Schuppan D, Popov YV. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer. Am J Physiol Gastrointest Liver Physiol 2020;318:G174-88. [PMID: 31630534 DOI: 10.1152/ajpgi.00041.2019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
137 Tziomalos K. Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World J Hepatol 2014;6:738-44. [PMID: 25349644 DOI: 10.4254/wjh.v6.i10.738] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
138 Pham T, Dick TB, Charlton MR. Nonalcoholic Fatty Liver Disease and Liver Transplantation. Clin Liver Dis 2016;20:403-17. [PMID: 27063277 DOI: 10.1016/j.cld.2015.10.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
139 Armstrong MJ, Barton D, Gaunt P, Hull D, Guo K, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open. 2013;3:e003995. [PMID: 24189085 DOI: 10.1136/bmjopen-2013-003995] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
140 Hartl L, Elias J, Prager G, Reiberger T, Unger LW. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. World J Gastroenterol 2021;27:2281-98. [PMID: 34040322 DOI: 10.3748/wjg.v27.i19.2281] [Reference Citation Analysis]
141 Zhu Y, Zhao H, Lu J, Lin K, Ni J, Wu G, Tang H. Caspase-11-Mediated Hepatocytic Pyroptosis Promotes the Progression of Nonalcoholic Steatohepatitis. Cell Mol Gastroenterol Hepatol 2021;12:653-64. [PMID: 33894425 DOI: 10.1016/j.jcmgh.2021.04.009] [Reference Citation Analysis]
142 Cruz JF, Ferrari YAC, Machado CP, Santana NN, Mota AVH, Lima SO. SARCOPENIA AND SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE. Arq Gastroenterol 2019;56:357-60. [PMID: 31618396 DOI: 10.1590/S0004-2803.201900000-66] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
143 Hajifathalian K, Torabi Sagvand B, McCullough AJ. Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. Hepatology 2019;70:511-21. [PMID: 30125379 DOI: 10.1002/hep.30226] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 13.3] [Reference Citation Analysis]
144 Stefan N. [New aspects of nonalcoholic steatohepatitis]. Internist (Berl) 2019;60:128-32. [PMID: 30645665 DOI: 10.1007/s00108-018-0550-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
145 Zhou B, Zhou DL, Wei XH, Zhong RY, Xu J, Sun L. Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation. Acta Pharmacol Sin 2017;38:998-1008. [PMID: 28344322 DOI: 10.1038/aps.2016.175] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
146 Haufe S, Hupa-Breier KL, Bayerle P, Boeck HT, Rolff S, Sundermeier T, Kerling A, Eigendorf J, Kück M, Hanke AA, Ensslen R, Nachbar L, Lauenstein D, Böthig D, Hilfiker-Kleiner D, Stiesch M, Terkamp C, Wedemeyer H, Haverich A, Tegtbur U. Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. Clin Transl Gastroenterol 2021;12:e00371. [PMID: 34140456 DOI: 10.14309/ctg.0000000000000371] [Reference Citation Analysis]
147 Chung M, Ma J, Patel K, Berger S, Lau J, Lichtenstein AH. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr 2014;100:833-49. [PMID: 25099546 DOI: 10.3945/ajcn.114.086314] [Cited by in Crossref: 126] [Cited by in F6Publishing: 111] [Article Influence: 18.0] [Reference Citation Analysis]
148 Tziomalos K, Athyros VG, Paschos P, Karagiannis A. Nonalcoholic fatty liver disease and statins. Metabolism. 2015;64:1215-1223. [PMID: 26234727 DOI: 10.1016/j.metabol.2015.07.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
149 Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123-133. [PMID: 28802062 DOI: 10.1002/hep.29466] [Cited by in Crossref: 594] [Cited by in F6Publishing: 501] [Article Influence: 148.5] [Reference Citation Analysis]
150 Horai Y, Utsumi H, Ono Y, Kishimoto T, Ono Y, Fukunari A. Pathological characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an experimental non-alcoholic steatohepatitis model, induced by high-fat and high-cholesterol diet. Int J Exp Pathol 2016;97:75-85. [PMID: 27037502 DOI: 10.1111/iep.12169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
151 Lim HW, Bernstein DE. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics. Clin Liver Dis 2018;22:39-57. [PMID: 29128060 DOI: 10.1016/j.cld.2017.08.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
152 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
153 Barr J, Caballería J, Martínez-Arranz I, Domínguez-Díez A, Alonso C, Muntané J, Pérez-Cormenzana M, García-Monzón C, Mayo R, Martín-Duce A, Romero-Gómez M, Lo Iacono O, Tordjman J, Andrade RJ, Pérez-Carreras M, Le Marchand-Brustel Y, Tran A, Fernández-Escalante C, Arévalo E, García-Unzueta M, Clement K, Crespo J, Gual P, Gómez-Fleitas M, Martínez-Chantar ML, Castro A, Lu SC, Vázquez-Chantada M, Mato JM. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res 2012;11:2521-32. [PMID: 22364559 DOI: 10.1021/pr201223p] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 13.9] [Reference Citation Analysis]
154 Chen K, Chen X, Xue H, Zhang P, Fang W, Chen X, Ling W. Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway. Food Funct 2019;10:814-23. [DOI: 10.1039/c8fo01236a] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 12.5] [Reference Citation Analysis]
155 Yi M, Chen RP, Yang R, Chen H. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China. Diabet Med 2017;34:505-13. [PMID: 27334577 DOI: 10.1111/dme.13174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
156 Motola DL, Caravan P, Chung RT, Fuchs BC. Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Curr Pathobiol Rep 2014;2:245-56. [PMID: 25396099 DOI: 10.1007/s40139-014-0061-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
157 Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513-1524. [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020] [Cited by in Crossref: 487] [Cited by in F6Publishing: 431] [Article Influence: 69.6] [Reference Citation Analysis]
158 Tsuma Y, Mori J, Ota T, Kawabe Y, Morimoto H, Fukuhara S, Kodo K, Umemura A, Nakajima H, Hosoi H. Erythropoietin and long-acting erythropoiesis stimulating agent ameliorate non-alcoholic fatty liver disease by increasing lipolysis and decreasing lipogenesis via EPOR/STAT pathway. Biochem Biophys Res Commun 2019;509:306-13. [PMID: 30583863 DOI: 10.1016/j.bbrc.2018.12.131] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
159 Schröder T, Kucharczyk D, Bär F, Pagel R, Derer S, Jendrek ST, Sünderhauf A, Brethack AK, Hirose M, Möller S, Künstner A, Bischof J, Weyers I, Heeren J, Koczan D, Schmid SM, Divanovic S, Giles DA, Adamski J, Fellermann K, Lehnert H, Köhl J, Ibrahim S, Sina C. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis. Mol Metab 2016;5:283-95. [PMID: 27069868 DOI: 10.1016/j.molmet.2016.01.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
160 Fiorentino TV, Succurro E, Sciacqua A, Andreozzi F, Perticone F, Sesti G. Non‐alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance. Diabetes Metab Res Rev 2020;36. [DOI: 10.1002/dmrr.3333] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
161 Noureddin N, Noureddin M, Singh A, Alkhouri N. Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes. Dig Dis Sci 2021. [PMID: 33779880 DOI: 10.1007/s10620-021-06955-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017;24:1073274817729245. [PMID: 28975830 DOI: 10.1177/1073274817729245] [Cited by in Crossref: 155] [Cited by in F6Publishing: 136] [Article Influence: 51.7] [Reference Citation Analysis]
163 Glaser T, Baiocchi L, Zhou T, Francis H, Lenci I, Grassi G, Kennedy L, Liangpunsakul S, Glaser S, Alpini G, Meng F. Pro-inflammatory signalling and gut-liver axis in non-alcoholic and alcoholic steatohepatitis: Differences and similarities along the path. J Cell Mol Med. 2020;24:5955-5965. [PMID: 32314869 DOI: 10.1111/jcmm.15182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
164 Ross AB, Godin JP, Minehira K, Kirwan JP. Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. Int J Endocrinol. 2013;2013:585876. [PMID: 23762052 DOI: 10.1155/2013/585876] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
165 Yilmaz B, Koklu S, Buyukbayram H, Yalçin K, Korkmaz U, Posul E, Can G, Kurt M. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis. Afr Health Sci 2015;15:714-8. [PMID: 26957957 DOI: 10.4314/ahs.v15i3.3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
166 Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013;167:1109-1117. [PMID: 23141876 DOI: 10.1016/j.ijcard.2012.09.085] [Cited by in Crossref: 55] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
167 Tonomura S, Naka S, Tabata K, Hara T, Mori K, Tanaka S, Sumida Y, Kanemasa K, Nomura R, Matsumoto-Nakano M, Ihara M, Takahashi N, Nakano K. Relationship between Streptococcus mutans expressing Cnm in the oral cavity and non-alcoholic steatohepatitis: a pilot study. BMJ Open Gastroenterol 2019;6:e000329. [PMID: 31645988 DOI: 10.1136/bmjgast-2019-000329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Liu W, Baker RD, Bhatia T, Zhu L, Baker SS. Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci. 2016;73:1969-1987. [PMID: 26894897 DOI: 10.1007/s00018-016-2161-x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 83] [Article Influence: 18.2] [Reference Citation Analysis]
169 Fox RK. When to Consider Liver Transplant During the Management of Chronic Liver Disease. Medical Clinics of North America 2014;98:153-68. [DOI: 10.1016/j.mcna.2013.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
170 Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol. 2013;23:483-491. [PMID: 23876851 DOI: 10.1016/j.semcancer.2013.07.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 8.9] [Reference Citation Analysis]
171 Bredella MA. Sex Differences in Body Composition. Adv Exp Med Biol 2017;1043:9-27. [PMID: 29224088 DOI: 10.1007/978-3-319-70178-3_2] [Cited by in Crossref: 74] [Cited by in F6Publishing: 45] [Article Influence: 24.7] [Reference Citation Analysis]
172 Muriel P. The Liver. Liver Pathophysiology. Elsevier; 2017. pp. 3-22. [DOI: 10.1016/b978-0-12-804274-8.00001-1] [Cited by in Crossref: 10] [Article Influence: 2.5] [Reference Citation Analysis]
173 Filozof C, Goldstein BJ, Williams RN, Sanyal A. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs 2015;75:1373-92. [PMID: 26201461 DOI: 10.1007/s40265-015-0437-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 9.4] [Reference Citation Analysis]
174 Vuppalanchi R, Siddiqui MS, Van Natta ML, Hallinan E, Brandman D, Kowdley K, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Abdelmalek M, Doo E, Tonascia JA, Kleiner DE, Sanyal AJ, Chalasani N; NASH Clinical Research Network. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology 2018;67:134-44. [PMID: 28859228 DOI: 10.1002/hep.29489] [Cited by in Crossref: 100] [Cited by in F6Publishing: 67] [Article Influence: 25.0] [Reference Citation Analysis]
175 Park H, Jang JE, Ko MS, Woo SH, Kim BJ, Kim HS, Park HS, Park I, Koh EH, Lee K. Statins Increase Mitochondrial and Peroxisomal Fatty Acid Oxidation in the Liver and Prevent Non-Alcoholic Steatohepatitis in Mice. Diabetes Metab J 2016;40:376. [DOI: 10.4093/dmj.2016.40.5.376] [Cited by in Crossref: 99] [Cited by in F6Publishing: 35] [Article Influence: 19.8] [Reference Citation Analysis]
176 Xin XM, Zhong MX, Yang GL, Peng Y, Zhang YL, Zhu W. GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells. World J Gastroenterol 2014;20:15727-35. [PMID: 25400456 DOI: 10.3748/wjg.v20.i42.15727] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
177 Keramida G, Hunter J, Dizdarevic S, Peters AM. Heterogeneity of intrahepatic fat distribution determined by 18F-FDG PET and CT. Ann Nucl Med 2016;30:200-6. [DOI: 10.1007/s12149-015-1045-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
178 Wainwright P, Scorletti E, Byrne CD. Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis. Curr Diab Rep 2017;17. [DOI: 10.1007/s11892-017-0851-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
179 Grattagliano I, Di Ciaula A, Baj J, Molina-Molina E, Shanmugam H, Garruti G, Wang DQ, Portincasa P. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). Methods Mol Biol 2021;2310:201-46. [PMID: 34096005 DOI: 10.1007/978-1-0716-1433-4_12] [Reference Citation Analysis]
180 Nirengi S, Fujibayashi M, Furuno S, Uchibe A, Kawase Y, Sukino S, Kawaguchi Y, Minato S, Kotani K, Sakane N. Nonalcoholic Fatty Liver Disease in University Rugby Football Players. Front Endocrinol (Lausanne) 2018;9:341. [PMID: 29973915 DOI: 10.3389/fendo.2018.00341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
181 García-Monzón C, Vargas-Castrillón J, Porrero JL, Alonso MT, Bonachía O, Castillo MJ, Marcos A, Quirós E, Ramos B, Sánchez-Cabezudo C, Villar S, Sáez A, Rodríguez de Cía J, del Pozo E, Vega-Piris L, Soto-Fernández S, Lo Iacono O, Miquilena-Colina ME. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones. Liver Int 2015;35:1983-91. [PMID: 25708133 DOI: 10.1111/liv.12813] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
182 Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015;38:1347-1355. [PMID: 25887357 DOI: 10.2337/dc14-1239] [Cited by in Crossref: 101] [Cited by in F6Publishing: 77] [Article Influence: 16.8] [Reference Citation Analysis]
183 Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. World J Gastroenterol. 2015;21:12989-12995. [PMID: 26675364 DOI: 10.3748/wjg.v21.i46.12989] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
184 Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract. 2013;28:40-51. [PMID: 23286927 DOI: 10.1177/0884533612470464] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
185 Drescher HK, Weiskirchen S, Weiskirchen R. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Cells 2019;8:E845. [PMID: 31394730 DOI: 10.3390/cells8080845] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 22.5] [Reference Citation Analysis]
186 Ma H, Xu CF, Shen Z, Yu CH, Li YM. Application of Machine Learning Techniques for Clinical Predictive Modeling: A Cross-Sectional Study on Nonalcoholic Fatty Liver Disease in China. Biomed Res Int 2018;2018:4304376. [PMID: 30402478 DOI: 10.1155/2018/4304376] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
187 Conway RBN, Sudenga S, McClain D, Blot WJ. Diabetes and liver cancer risk: A stronger effect in Whites than Blacks? J Diabetes Complications 2021;35:107816. [PMID: 33323327 DOI: 10.1016/j.jdiacomp.2020.107816] [Reference Citation Analysis]
188 Labyed Y, Milkowski A. Novel Method for Ultrasound‐Derived Fat Fraction Using an Integrated Phantom. J Ultrasound Med 2020;39:2427-38. [DOI: 10.1002/jum.15364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
189 Stefan N. Nonalcoholic Fatty Liver Disease and Coronary Artery Calcification. Clin Gastroenterol Hepatol 2016;14:1345-6. [PMID: 27237428 DOI: 10.1016/j.cgh.2016.05.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
190 Polyzos SA, Kountouras J, Patsiaoura K, Katsiki E, Zafeiriadou E, Deretzi G, Zavos C, Gavalas E, Katsinelos P, Mane V, Slavakis A. Serum homocysteine levels in patients with nonalcoholic fatty liver disease. Annals of Hepatology 2012;11:68-76. [DOI: 10.1016/s1665-2681(19)31488-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
191 Lazo M, Bilal U, Perez-Escamilla R. Epidemiology of NAFLD and Type 2 Diabetes: Health Disparities Among Persons of Hispanic Origin. Curr Diab Rep 2015;15:116. [PMID: 26468154 DOI: 10.1007/s11892-015-0674-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
192 Neuschwander-tetri BA. Farnesoid X Receptor Agonists: What They Are and How They Might Be Used in Treating Liver Disease. Curr Gastroenterol Rep 2012;14:55-62. [DOI: 10.1007/s11894-011-0232-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
193 Geh D, Rana FA, Reeves HL. Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. J Hepatocell Carcinoma 2019;6:23-30. [PMID: 30666302 DOI: 10.2147/JHC.S159581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
194 Hannah WN Jr, Harrison SA. Nonalcoholic fatty liver disease and elastography: Incremental advances but work still to be done. Hepatology. 2016;63:1762-1764. [PMID: 26891023 DOI: 10.1002/hep.28504] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
195 Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH, Li YM. Prevalence of Nonalcoholic Fatty Liver Disease and Economy. Dig Dis Sci 2015;60:3194-202. [PMID: 26017679 DOI: 10.1007/s10620-015-3728-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
196 Xiao J, Liong EC, Ching YP, Chang RC, Fung ML, Xu AM, So KF, Tipoe GL. Lycium barbarum polysaccharides protect rat liver from non-alcoholic steatohepatitis-induced injury. Nutr Diabetes 2013;3:e81. [PMID: 23877747 DOI: 10.1038/nutd.2013.22] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
197 Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res. 2015;45:20-28. [PMID: 24661406 DOI: 10.1111/hepr.12333] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 8.1] [Reference Citation Analysis]
198 Touzin NT, Bush KN, Williams CD, Harrison SA. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2011;4:169-176. [PMID: 21694801 DOI: 10.1177/1756283x11402118] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
199 Rantakokko P, Männistö V, Airaksinen R, Koponen J, Viluksela M, Kiviranta H, Pihlajamäki J. Persistent organic pollutants and non-alcoholic fatty liver disease in morbidly obese patients: a cohort study. Environ Health 2015;14:79. [PMID: 26420011 DOI: 10.1186/s12940-015-0066-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
200 Yang YJ, Kim T, Hong YP. Urinary Phthalate Levels Associated with the Risk of Nonalcoholic Fatty Liver Disease in Adults: The Korean National Environmental Health Survey (KoNEHS) 2012-2014. Int J Environ Res Public Health 2021;18:6035. [PMID: 34199698 DOI: 10.3390/ijerph18116035] [Reference Citation Analysis]
201 Yki-Järvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia. 2016;59:1104-1111. [PMID: 27091184 DOI: 10.1007/s00125-016-3944-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 9.6] [Reference Citation Analysis]
202 McPherson S, Anstee QM, Henderson E, Day CP, Burt AD. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol. 2013;25:652-658. [PMID: 23325287 DOI: 10.1097/meg.0b013e32835d72cf] [Cited by in Crossref: 49] [Cited by in F6Publishing: 22] [Article Influence: 6.1] [Reference Citation Analysis]
203 Carvalhana S, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver Int. 2014;34:e111-e117. [PMID: 24034415 DOI: 10.1111/liv.12305] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
204 Lee S, Ko BJ, Gong Y, Han K, Lee A, Han BD, Yoon YJ, Park S, Kim JH, Mantzoros CS. Self-reported eating speed in relation to non-alcoholic fatty liver disease in adults. Eur J Nutr 2016;55:327-33. [PMID: 25648740 DOI: 10.1007/s00394-015-0851-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
205 Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-318. [PMID: 23458891 DOI: 10.1038/nrgastro.2013.34] [Cited by in Crossref: 278] [Cited by in F6Publishing: 244] [Article Influence: 34.8] [Reference Citation Analysis]
206 Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, May SB, Kramer JR, Richardson PA, Davila JA. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015;13:594-601.e1. [PMID: 25148760 DOI: 10.1016/j.cgh.2014.08.013] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 20.4] [Reference Citation Analysis]
207 López-velázquez JA, Silva-vidal KV, Ponciano-rodríguez G, Chávez-tapia NC, Arrese M, Uribe M, Méndez-sánchez N. The prevalence of nonalcoholic fatty liver disease in the Americas. Annals of Hepatology 2014;13:166-78. [DOI: 10.1016/s1665-2681(19)30879-8] [Cited by in Crossref: 82] [Article Influence: 11.7] [Reference Citation Analysis]
208 Patel YA, Henao R, Moylan CA, Guy CD, Piercy DL, Diehl AM, Abdelmalek MF. Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis. Am J Gastroenterol 2016;111:1591-8. [PMID: 27644736 DOI: 10.1038/ajg.2016.406] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
209 Ait Boudaoud A, Rives-Lange C, Perregaux JF, Radu A, Messager-Josipowicz D, Barsamian C, Carette C, Czernichow S. [Nutritional Management of Nonalcoholic fatty liver disease (NAFLD)]. Presse Med 2019;48:1496-501. [PMID: 31757727 DOI: 10.1016/j.lpm.2019.10.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
210 Chen M, Xing J, Pan D, Peng X, Gao P. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway. Biomed Pharmacother 2020;128:110286. [PMID: 32521450 DOI: 10.1016/j.biopha.2020.110286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Kogachi S, Noureddin M. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Ther 2021;43:455-72. [PMID: 33581876 DOI: 10.1016/j.clinthera.2021.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
212 Falade-Nwulia O, Thio CL. Liver disease, HIV and aging. Sex Health 2011;8:512-20. [PMID: 22127037 DOI: 10.1071/SH10163] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
213 Dierssen M, Fructuoso M, Martínez de Lagrán M, Perluigi M, Barone E. Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions. Front Neurosci 2020;14:670. [PMID: 32733190 DOI: 10.3389/fnins.2020.00670] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
214 Guo XY, Sun F, Chen JN, Wang YQ, Pan Q, Fan JG. circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling. World J Gastroenterol. 2018;24:323-337. [PMID: 29391755 DOI: 10.3748/wjg.v24.i3.323] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
215 Farooque U, Lohano AK, Dahri Q, Arain N, Farukhuddin F, Khadke C, Prince F, Farooque R, Shehata MA, Bin Zafar MD. The Pattern of Dyslipidemia in Chronic Liver Disease Patients. Cureus 2021;13:e13259. [PMID: 33728198 DOI: 10.7759/cureus.13259] [Reference Citation Analysis]
216 Charlton MR. Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn't there). Gastroenterology 2011;140:25-8. [PMID: 21110967 DOI: 10.1053/j.gastro.2010.11.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
217 Weiskirchen R, Tacke F. The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis. Curr Hepatology Rep 2018;17:324-35. [DOI: 10.1007/s11901-018-0421-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
218 Sun P, Zeng Q, Cheng D, Zhang K, Zheng J, Liu Y, Yuan Y, Tang Y. Caspase Recruitment Domain Protein 6 Protects Against Hepatic Steatosis and Insulin Resistance by Suppressing Apoptosis Signal-Regulating Kinase 1. Hepatology 2018;68:2212-29. [DOI: 10.1002/hep.30075] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
219 Duseja A, Chalasani N. Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). Hepatol Int 2013;7 Suppl 2:755-64. [PMID: 26202291 DOI: 10.1007/s12072-013-9480-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
220 Lorbek G, Urlep Ž, Rozman D. Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease. Pharmacogenomics 2016;17:1273-88. [PMID: 27377717 DOI: 10.2217/pgs-2016-0047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
221 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359.e2. [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.001] [Cited by in Crossref: 413] [Cited by in F6Publishing: 369] [Article Influence: 45.9] [Reference Citation Analysis]
222 Li CL, Zhou WJ, Ji G, Zhang L. Natural products that target macrophages in treating non-alcoholic steatohepatitis. World J Gastroenterol 2020;26:2155-65. [PMID: 32476782 DOI: 10.3748/wjg.v26.i18.2155] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
223 Taylor E, Huang N, Bodde J, Ellison A, Killiany R, Bachschmid MM, Hamilton J. MRI of atherosclerosis and fatty liver disease in cholesterol fed rabbits. J Transl Med 2018;16:215. [PMID: 30068362 DOI: 10.1186/s12967-018-1587-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 De A, Duseja A. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. J Clin Exp Hepatol 2020;10:255-62. [PMID: 32405182 DOI: 10.1016/j.jceh.2019.09.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
225 Kutlu O, Altun Ö, Dikker O, Aktaş Ş, Özsoy N, Arman Y, Özgün Çil E, Özcan M, Aydın Yoldemir Ş, Akarsu M, Toprak İD, Kırna K, Kutlu Y, Toprak Z, Eruzun H, Tükek T. Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease. Med Princ Pract 2019;28:463-9. [PMID: 30995640 DOI: 10.1159/000500106] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
226 d'Assignies G, Fayard C, Leitao H, Alfaiate T, Tubach F, Dokmak S, Paradis V, Van Beers BE, Ronot M, Vilgrain V. Liver steatosis assessed by preoperative MRI: An independent risk factor for severe complications after major hepatic resection. Surgery 2016;159:1050-7. [DOI: 10.1016/j.surg.2015.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
227 Kroh A, Ivanova V, Drescher H, Andruszkow J, Longerich T, Nolting J, Eickhoff R, Heise D, Rheinwalt KP, Neumann UP, Ulmer FT. Mouse Models of Nonalcoholic Steatohepatitis: Head-to-Head Comparison of Dietary Models and Impact on Inflammation and Animal Welfare. Gastroenterol Res Pract 2020;2020:7347068. [PMID: 32765601 DOI: 10.1155/2020/7347068] [Reference Citation Analysis]
228 Salloum S, Jeyarajan AJ, Kruger AJ, Holmes JA, Shao T, Sojoodi M, Kim MH, Zhuo Z, Shroff SG, Kassa A, Corey KE, Khan SK, Lin W, Alatrakchi N, Schaefer EAK, Chung RT. Fatty Acids Activate the Transcriptional Coactivator YAP1 to Promote Liver Fibrosis via p38 Mitogen-Activated Protein Kinase. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00118-1. [PMID: 34118488 DOI: 10.1016/j.jcmgh.2021.06.003] [Reference Citation Analysis]
229 Akinkugbe AA, Avery CL, Barritt AS, Cole SR, Lerch M, Mayerle J, Offenbacher S, Petersmann A, Nauck M, Völzke H, Slade GD, Heiss G, Kocher T, Holtfreter B. Do Genetic Markers of Inflammation Modify the Relationship between Periodontitis and Nonalcoholic Fatty Liver Disease? Findings from the SHIP Study. J Dent Res 2017;96:1392-9. [PMID: 28732187 DOI: 10.1177/0022034517720924] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
230 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
231 Ajmera V, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE, Neuschwander-Tetri BA, Terrault N; Nonalcoholic Steatohepatitis Clinical Research Network. Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol 2018;16:1511-1520.e5. [PMID: 29378307 DOI: 10.1016/j.cgh.2018.01.026] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
232 Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015;21:11053-76. [PMID: 26494962 DOI: 10.3748/wjg.v21.i39.11053] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
233 Devadason CA, Scheimann AO. Overview of screening methods for fatty liver disease in children. World J Hepatol. 2012;4:1-4. [PMID: 22312449 DOI: 10.4254/wjh.v4.i1.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
234 Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients. J Viral Hepat 2015;22:800-8. [DOI: 10.1111/jvh.12394] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
235 Entezari MR, Talenezhad N, Mirzavandi F, Rahimpour S, Mozaffari-Khosravi H, Fallahzadeh H, Hosseinzadeh M. Mediterranean dietary pattern and non-alcoholic fatty liver diseases: a case-control study. J Nutr Sci 2021;10:e55. [PMID: 34367629 DOI: 10.1017/jns.2021.43] [Reference Citation Analysis]
236 Thuluvath PJ, Amjad W, Zhang T. Liver transplant waitlist removal, transplantation rates and post-transplant survival in Hispanics. PLoS One 2020;15:e0244744. [PMID: 33382811 DOI: 10.1371/journal.pone.0244744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
237 Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, Argo CK. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-703. [PMID: 30136293 DOI: 10.1111/apt.14937] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 23.7] [Reference Citation Analysis]
238 Barry CT, Hazard C, Hah Z, Cheng G, Partin A, Mooney RA, Chuang K, Cao W, Rubens DJ, Parker KJ. Shear Wave Dispersion in Lean Versus Steatotic Rat Livers. Journal of Ultrasound in Medicine 2015;34:1123-9. [DOI: 10.7863/ultra.34.6.1123] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
239 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 50] [Article Influence: 20.3] [Reference Citation Analysis]
240 Wan X, Xu C, Lin Y, Lu C, Li D, Sang J, He H, Liu X, Li Y, Yu C. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64:925-932. [PMID: 26639394 DOI: 10.1016/j.jhep.2015.11.022] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 12.3] [Reference Citation Analysis]
241 Hsu CC, Ness E, Kowdley KV. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. Adv Nutr. 2017;8:253-265. [PMID: 28298270 DOI: 10.3945/an.116.013730] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
242 Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017;9:715-732. [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715] [Cited by in Crossref: 290] [Cited by in F6Publishing: 228] [Article Influence: 72.5] [Reference Citation Analysis]
243 Geidl-Flueck B, Gerber PA. Insights into the Hexose Liver Metabolism-Glucose versus Fructose. Nutrients 2017;9:E1026. [PMID: 28926951 DOI: 10.3390/nu9091026] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
244 Tortora R, Rispo A, Alisi A, Imperatore N, Crudele A, Ferretti F, Nobili V, Miele L, Gerbino N, Caporaso N, Morisco F. PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease. Nutrients 2018;10:E1239. [PMID: 30189691 DOI: 10.3390/nu10091239] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
245 Ding H, Huang JF, Xie HS, Wang BY, Lin T, Zhao JM, Lin QC. The association between glycometabolism and nonalcoholic fatty liver disease in patients with obstructive sleep apnea. Sleep Breath 2019;23:373-8. [PMID: 30349997 DOI: 10.1007/s11325-018-1744-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
246 Toesca DAS, Barry A, Sapisochin G, Beecroft R, Dawson L, Owen D, Mouli S, Lewandowski R, Salem R, Chang DT. Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:295-308. [PMID: 30309640 DOI: 10.1016/j.semradonc.2018.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
247 Dennis A, Mouchti S, Kelly M, Fallowfield JA, Hirschfield G, Pavlides M, Banerjee R. A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis. Sci Rep 2020;10:15308. [PMID: 32943694 DOI: 10.1038/s41598-020-71995-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
248 Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429-436. [PMID: 21987293 DOI: 10.1002/hep.24731] [Cited by in Crossref: 198] [Cited by in F6Publishing: 157] [Article Influence: 19.8] [Reference Citation Analysis]
249 Li Y, Sun JP, Wang J, Lu WH, Xie LY, Lv J, Li HX, Yang SF. Expression of Vsig4 attenuates macrophage-mediated hepatic inflammation and fibrosis in high fat diet (HFD)-induced mice. Biochem Biophys Res Commun 2019;516:858-65. [PMID: 31266632 DOI: 10.1016/j.bbrc.2019.06.045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
250 El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;20:E2215. [PMID: 31064058 DOI: 10.3390/ijms20092215] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
251 Candia R, Ruiz A, Torres-Robles R, Chávez-Tapia N, Méndez-Sánchez N, Arrese M. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29:656-662. [PMID: 25418531 DOI: 10.1111/jdv.12847] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 8.1] [Reference Citation Analysis]
252 Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328-348. [PMID: 29846945 DOI: 10.1002/med.21515] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
253 Chiu C, Wang L, Liu S, Chiang M. Fish Oil Supplementation Alleviates the Altered Lipid Homeostasis in Blood, Liver, and Adipose Tissues in High-Fat Diet-Fed Rats. J Agric Food Chem 2018;66:4118-28. [DOI: 10.1021/acs.jafc.8b00529] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
254 Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab. 2013;27:195-208. [PMID: 23731881 DOI: 10.1016/j.beem.2013.02.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
255 Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, Chim AM, Lai JW, Li LS, Sea MM, Chan FK, Sung JJ, Woo J, Chan HL. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2013;59:536-542. [PMID: 23623998 DOI: 10.1016/j.jhep.2013.04.013] [Cited by in Crossref: 154] [Cited by in F6Publishing: 143] [Article Influence: 19.3] [Reference Citation Analysis]
256 Liu H, Zhong H, Yin Y, Jiang Z. Genistein has beneficial effects on hepatic steatosis in high fat-high sucrose diet-treated rats. Biomed Pharmacother 2017;91:964-9. [PMID: 28514835 DOI: 10.1016/j.biopha.2017.04.130] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
257 Jin R, Welsh JA, Le NA, Holzberg J, Sharma P, Martin DR, Vos MB. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients. 2014;6:3187-3201. [PMID: 25111123 DOI: 10.3390/nu6083187] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
258 Jonas W, Schürmann A. Genetic and epigenetic factors determining NAFLD risk. Mol Metab 2021;50:101111. [PMID: 33160101 DOI: 10.1016/j.molmet.2020.101111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
259 Feksa DL, Coelho RP, Aparecida da Costa Güllich A, Dal Ponte ES, da Costa Escobar Piccoli J, Manfredini V. Extract of Citrus maxima (pummelo) leaves improve hepatoprotective activity in Wistar rats submitted to the induction of non-alcoholic hepatic steatosis. Biomedicine & Pharmacotherapy 2018;98:338-46. [DOI: 10.1016/j.biopha.2017.12.070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
260 Ostovaneh MR, Zamani F, Ansari-moghaddam A, Sharafkhah M, Saeedian FS, Rohani Z, Khoonsari M, Barzin G, Hemmasi G, Ajdarkosh H, Katoonizadeh A, Maadi M, Malekzadeh R, Poustchi H. Nonalcoholic Fatty Liver: The Association with Metabolic Abnormalities, Body Mass Index and Central Obesity—A Population-Based Study. Metabolic Syndrome and Related Disorders 2015;13:304-11. [DOI: 10.1089/met.2014.0131] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
261 Palmer M, Jennings L, Silberg DG, Bliss C, Martin P. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol 2018;19:10. [PMID: 29548345 DOI: 10.1186/s40360-018-0200-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
262 Hong CW, Marsh A, Wolfson T, Paige J, Dekhordy SF, Schlein AN, Housman E, Deiranieh LH, Li CQ, Wasnik AP, Jang HJ, Dietrich CF, Piscaglia F, Casola G, O'Boyle M, Richman KM, Valasek MA, Andre M, Loomba R, Sirlin CB. Reader agreement and accuracy of ultrasound features for hepatic steatosis. Abdom Radiol (NY) 2019;44:54-64. [PMID: 29951900 DOI: 10.1007/s00261-018-1683-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
263 Portillo P, Yavuz S, Bril F, Cusi K. Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2014;13:159-70. [DOI: 10.1007/s11901-014-0229-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
264 Chen YJ, Wallig MA, Jeffery EH. Dietary Broccoli Lessens Development of Fatty Liver and Liver Cancer in Mice Given Diethylnitrosamine and Fed a Western or Control Diet. J Nutr 2016;146:542-50. [PMID: 26865652 DOI: 10.3945/jn.115.228148] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
265 Jain S, Thanage R, Panchal F, Rathi PM, Munshi R, Udgirkar SS, Contractor QQ, Chandnani SJ, Sujit NP, Debnath P, Singh A. Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link? J Clin Exp Hepatol 2021;11:466-74. [PMID: 34276153 DOI: 10.1016/j.jceh.2020.10.003] [Reference Citation Analysis]
266 Song M, Li X, Zhang X, Shi H, Vos MB, Wei X, Wang Y, Gao H, Rouchka EC, Yin X, Zhou Z, Prough RA, Cave MC, McClain CJ. Dietary copper-fructose interactions alter gut microbial activity in male rats. Am J Physiol Gastrointest Liver Physiol 2018;314:G119-30. [PMID: 29025734 DOI: 10.1152/ajpgi.00378.2016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
267 Shetty K, Chen J, Shin JH, Jogunoori W, Mishra L. Pathogenesis of hepatocellular carcinoma development in non alcoholic fatty liver disease. Curr Hepatol Rep. 2015;14:119-127. [PMID: 26114083 DOI: 10.1007/s11901-015-0260-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
268 Jiao N, Baker SS, Nugent CA, Tsompana M, Cai L, Wang Y, Buck MJ, Genco RJ, Baker RD, Zhu R, Zhu L. Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents: A meta-analysis. Physiol Genomics. 2018;50:244-254. [PMID: 29373083 DOI: 10.1152/physiolgenomics.00114.2017] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 25.0] [Reference Citation Analysis]
269 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch. 2011;458:511-523. [PMID: 21442288 DOI: 10.1007/s00428-011-1066-1] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 6.9] [Reference Citation Analysis]
270 Dixon A. The treatment of asthma in obesity. Expert Rev Respir Med 2012;6:331-40. [PMID: 22788947 DOI: 10.1586/ers.12.22] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
271 Orman ES, Barritt AS 4th, Wheeler SB, Hayashi PH. Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death. Liver Transpl 2013;19:59-68. [PMID: 22965893 DOI: 10.1002/lt.23547] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 10.8] [Reference Citation Analysis]
272 Loong TC, Wei JL, Leung JC, Wong GL, Shu SS, Chim AM, Chan AW, Choi PC, Tse YK, Chan HL, Wong VW. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2017;32:1363-1369. [PMID: 27936280 DOI: 10.1111/jgh.13671] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
273 Shaker M, Tabbaa A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol. 2014;20:5320-5330. [PMID: 24833862 DOI: 10.3748/wjg.v20.i18.5320] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 53] [Article Influence: 10.0] [Reference Citation Analysis]
274 Yu R, Shi Q, Liu L, Chen L. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis. BMC Gastroenterol 2018;18:51. [PMID: 29673321 DOI: 10.1186/s12876-018-0776-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 11.7] [Reference Citation Analysis]
275 Akazawa Y, Nakao K. To die or not to die: death signaling in nonalcoholic fatty liver disease. J Gastroenterol 2018;53:893-906. [PMID: 29574534 DOI: 10.1007/s00535-018-1451-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 12.3] [Reference Citation Analysis]
276 Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, Nitzan Kaluski D, Halpern Z, Oren R. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56:1145-1151. [PMID: 22245895 DOI: 10.1016/j.jhep.2011.12.011] [Cited by in Crossref: 148] [Cited by in F6Publishing: 127] [Article Influence: 16.4] [Reference Citation Analysis]
277 Mukhopadhya I, Hansen R, El-Omar EM, Hold GL. IBD-what role do Proteobacteria play? Nat Rev Gastroenterol Hepatol 2012;9:219-30. [PMID: 22349170 DOI: 10.1038/nrgastro.2012.14] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
278 Min-DeBartolo J, Schlerman F, Akare S, Wang J, McMahon J, Zhan Y, Syed J, He W, Zhang B, Martinez RV. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH). PLoS One 2019;14:e0226854. [PMID: 31891606 DOI: 10.1371/journal.pone.0226854] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
279 Cassidy S, Hallsworth K, Thoma C, MacGowan GA, Hollingsworth KG, Day CP, Taylor R, Jakovljevic DG, Trenell MI. Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control. Cardiovasc Diabetol 2015;14:23. [PMID: 25849783 DOI: 10.1186/s12933-015-0187-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
280 Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines (Basel). 2019;6. [PMID: 30889791 DOI: 10.3390/medicines6010041] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]
281 Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 2015;90:1233-46. [PMID: 26219858 DOI: 10.1016/j.mayocp.2015.06.013] [Cited by in Crossref: 127] [Cited by in F6Publishing: 101] [Article Influence: 21.2] [Reference Citation Analysis]
282 Mahady SE, Adams LA. Burden of non-alcoholic fatty liver disease in Australia: Burden of fatty liver in Australia. Journal of Gastroenterology and Hepatology 2018;33:1-11. [DOI: 10.1111/jgh.14270] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
283 Raveendran VV, Kassel KM, Smith DD, Luyendyk JP, Williams KJ, Cherian R, Reed GA, Flynn CA, Csanaky IL, Lickteig AL, Pratt-Hyatt MJ, Klaassen CD, Dileepan KN. H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice. Am J Physiol Gastrointest Liver Physiol 2014;307:G219-28. [PMID: 24852568 DOI: 10.1152/ajpgi.00027.2014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
284 Edula RG, Muthukuru S, Moroianu S, Wang Y, Lingiah V, Fung P, Pyrsopoulos NT. CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study. J Clin Transl Hepatol 2018;6:241-6. [PMID: 30271734 DOI: 10.14218/JCTH.2017.00070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
285 Tarantino G, Finelli C, Colao A, Capone D, Tarantino M, Grimaldi E, Chianese D, Gioia S, Pasanisi F, Contaldo F. Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase. J Transl Med. 2012;10:50. [PMID: 22424154 DOI: 10.1186/1479-5876-10-50] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
286 Hartleb M, Barański K, Zejda J, Chudek J, Więcek A. Non-alcoholic fatty liver and advanced fibrosis in the elderly: Results from a community-based Polish survey. Liver Int 2017;37:1706-14. [PMID: 28489307 DOI: 10.1111/liv.13471] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
287 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839.2014.12.06] [Cited by in F6Publishing: 73] [Reference Citation Analysis]
288 Nalbantoglu IL, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:9026-9037. [PMID: 25083076 DOI: 10.3748/wjg.v20.i27.9026] [Cited by in F6Publishing: 41] [Reference Citation Analysis]
289 Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism. 2016;65:1087-1095. [PMID: 26972222 DOI: 10.1016/j.metabol.2016.01.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
290 Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:8341-8350. [PMID: 25024593 DOI: 10.3748/wjg.v20.i26.8341] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
291 Lu Z, Li Y, Syn WK, Wang Z, Lopes-Virella MF, Lyons TJ, Huang Y. Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism. Am J Physiol Endocrinol Metab 2020;318:E131-44. [PMID: 31821039 DOI: 10.1152/ajpendo.00181.2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
292 Pathak R, Kumar A, Palfrey HA, Forney LA, Stone KP, Raju NR, Gettys TW, Murthy SN. The incretin enhancer, sitagliptin, exacerbates expression of hepatic inflammatory markers in rats fed a high-cholesterol diet. Inflamm Res 2019;68:581-95. [PMID: 31073849 DOI: 10.1007/s00011-019-01243-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
293 Paik J, Golabi P, Younoszai Z, Mishra A, Trimble G, Younossi ZM, Negro F. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver Int 2019;39:342-52. [DOI: 10.1111/liv.13992] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
294 Torres DM, Harrison SA. Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis. Hepatology 2015;61:1462-4. [PMID: 25564771 DOI: 10.1002/hep.27680] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
295 Morse CG. Fatty liver disease in HIV: common, underappreciated, and understudied. AIDS 2017;31:1633-5. [PMID: 28657965 DOI: 10.1097/QAD.0000000000001525] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
296 Giorgi C, Marchi S, Simoes ICM, Ren Z, Morciano G, Perrone M, Patalas-Krawczyk P, Borchard S, Jędrak P, Pierzynowska K, Szymański J, Wang DQ, Portincasa P, Węgrzyn G, Zischka H, Dobrzyn P, Bonora M, Duszynski J, Rimessi A, Karkucinska-Wieckowska A, Dobrzyn A, Szabadkai G, Zavan B, Oliveira PJ, Sardao VA, Pinton P, Wieckowski MR. Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases. Int Rev Cell Mol Biol 2018;340:209-344. [PMID: 30072092 DOI: 10.1016/bs.ircmb.2018.05.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 21.7] [Reference Citation Analysis]
297 Kallwitz ER, Daviglus ML, Allison MA, Emory KT, Zhao L, Kuniholm MH, Chen J, Gouskova N, Pirzada A, Talavera GA, Youngblood ME, Cotler SJ. Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage. Clin Gastroenterol Hepatol. 2015;13:569-576. [PMID: 25218670 DOI: 10.1016/j.cgh.2014.08.037] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
298 Cassinotto C, Boursier J, de Lédinghen V, Lebigot J, Lapuyade B, Cales P, Hiriart J, Michalak S, Bail BL, Cartier V, Mouries A, Oberti F, Fouchard-hubert I, Vergniol J, Aubé C. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy: Cassinotto et al. Hepatology 2016;63:1817-27. [DOI: 10.1002/hep.28394] [Cited by in Crossref: 235] [Cited by in F6Publishing: 185] [Article Influence: 47.0] [Reference Citation Analysis]
299 Arulanandan A, Loomba R. Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet? Curr Hepatol Rep 2015;14:109-18. [PMID: 26500833 DOI: 10.1007/s11901-015-0263-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
300 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 315] [Article Influence: 121.7] [Reference Citation Analysis]
301 Pimentel CF, Lai M. Nutrition Interventions for Chronic Liver Diseases and Nonalcoholic Fatty Liver Disease. Med Clin North Am. 2016;100:1303-1327. [PMID: 27745596 DOI: 10.1016/j.mcna.2016.06.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
302 Demirel-Yalciner T, Sozen E, Ozaltin E, Sahin A, Ozer NK. alpha-Tocopherol supplementation reduces inflammation and apoptosis in high cholesterol mediated nonalcoholic steatohepatitis. Biofactors 2021;47:403-13. [PMID: 34101924 DOI: 10.1002/biof.1700] [Reference Citation Analysis]
303 Bieghs V, Trautwein C. Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2014;3:377-385. [PMID: 25568861 DOI: 10.3978/j.issn.2304-3881.2014.12.04] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
304 Lin IT, Lee MY, Wang CW, Wu DW, Chen SC. Gender Differences in the Relationships among Metabolic Syndrome and Various Obesity-Related Indices with Nonalcoholic Fatty Liver Disease in a Taiwanese Population. Int J Environ Res Public Health 2021;18:857. [PMID: 33498329 DOI: 10.3390/ijerph18030857] [Reference Citation Analysis]
305 Sayiner M, Otgonsuren M, Cable R, Younossi I, Afendy M, Golabi P, Henry L, Younossi ZM. Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis. J Clin Gastroenterol 2017;51:254-60. [PMID: 27332747 DOI: 10.1097/MCG.0000000000000567] [Cited by in Crossref: 44] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
306 Liu P, Lin H, Xu Y, Zhou F, Wang J, Liu J, Zhu X, Guo X, Tang Y, Yao P. Frataxin-Mediated PINK1-Parkin-Dependent Mitophagy in Hepatic Steatosis: The Protective Effects of Quercetin. Mol Nutr Food Res 2018;62:e1800164. [PMID: 29935106 DOI: 10.1002/mnfr.201800164] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 11.3] [Reference Citation Analysis]
307 Gao B, Sakaguchi K, Ogawa T, Kagawa Y, Kubo H, Shimizu T. Functional Analysis of Induced Human Ballooned Hepatocytes in a Cell Sheet-Based Three Dimensional Model. Tissue Eng Regen Med 2021;18:217-24. [PMID: 33517537 DOI: 10.1007/s13770-020-00297-x] [Reference Citation Analysis]
308 Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun 2018;2:48-57. [PMID: 29404512 DOI: 10.1002/hep4.1124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 66] [Article Influence: 20.0] [Reference Citation Analysis]
309 Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani N, Lee WM, Stolz A, Phillips T, Serrano J, Watkins PB; DILIN Investigators. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.Am J Gastroenterol. 2015;110:1450-1459. [PMID: 26346867 DOI: 10.1038/ajg.2015.283] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 10.7] [Reference Citation Analysis]
310 Okamura K, Okuda T, Takamiya Y, Shirai K, Urata H. High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. Heart Vessels 2019;34:1559-69. [PMID: 30919112 DOI: 10.1007/s00380-019-01391-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
311 Hu XN, Wang JF, Huang YQ, Wang Z, Dong FY, Ma HF, Bao ZJ. Huperzine A attenuates nonalcoholic fatty liver disease by regulating hepatocyte senescence and apoptosis: an in vitro study. PeerJ 2018;6:e5145. [PMID: 29967757 DOI: 10.7717/peerj.5145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
312 Erion DM, Park HJ, Lee HY. The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Rep. 2016;49:139-148. [PMID: 26728273 DOI: 10.5483/bmbrep.2016.49.3.268] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
313 Dhaliwal HS, Singh R, Abraham AM, Sharma R, Goyal NK, Soloman R, Bansal P, Goyal A. Perception of Illness and Its Association with Treatment Willingness in Patients with Newly Diagnosed Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 33409801 DOI: 10.1007/s10620-020-06794-2] [Reference Citation Analysis]
314 Corey KE, Chalasani N. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:1077-84; quiz e59-60. [PMID: 23962548 DOI: 10.1016/j.cgh.2013.08.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
315 Cheung A, Figueredo C, Rinella ME. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol 2019;114:579-90. [PMID: 30839326 DOI: 10.14309/ajg.0000000000000058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
316 Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, Haupt A. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab. 2017;19:1630-1634. [PMID: 28417532 DOI: 10.1111/dom.12973] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 17.5] [Reference Citation Analysis]
317 Zhou Y, Wei F, Fan Y. High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin Biochem. 2016;49:636-642. [PMID: 26738417 DOI: 10.1016/j.clinbiochem.2015.12.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
318 Han MA, Saouaf R, Ayoub W, Todo T, Mena E, Noureddin M. Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). Expert Rev Clin Pharmacol. 2017;10:379-390. [PMID: 28277807 DOI: 10.1080/17512433.2017.1299573] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
319 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ;  American Gastroenterological Association;  American Association for the Study of Liver Diseases;  American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609. [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001] [Cited by in Crossref: 1078] [Cited by in F6Publishing: 947] [Article Influence: 119.8] [Reference Citation Analysis]
320 Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One. 2012;7:e38322. [PMID: 22719876 DOI: 10.1371/journal.pone.0038322] [Cited by in Crossref: 171] [Cited by in F6Publishing: 154] [Article Influence: 19.0] [Reference Citation Analysis]
321 Allen AM, Shah VH, Therneau TM, Venkatesh SK, Mounajjed T, Larson JJ, Mara KC, Kellogg TA, Kendrick ML, McKenzie TJ, Greiner SM, Li J, Glaser KJ, Wells ML, Gunneson TJ, Ehman RL, Yin M. Multiparametric Magnetic Resonance Elastography Improves the Detection of NASH Regression Following Bariatric Surgery. Hepatol Commun 2020;4:185-92. [PMID: 32025604 DOI: 10.1002/hep4.1446] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
322 Cui J, Heba E, Hernandez C, Haufe W, Hooker J, Andre MP, Valasek MA, Aryafar H, Sirlin CB, Loomba R. Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study. Hepatology. 2016;63:453-461. [PMID: 26560734 DOI: 10.1002/hep.28337] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 20.8] [Reference Citation Analysis]
323 Bonekamp S, Tang A, Mashhood A, Wolfson T, Changchien C, Middleton MS, Clark L, Gamst A, Loomba R, Sirlin CB. Spatial distribution of MRI-determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease: Spatial Distribution of Liver Fat in NAFLD. J Magn Reson Imaging 2014;39:1525-32. [DOI: 10.1002/jmri.24321] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
324 Karagozian R, Derdák Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 2014;63:607-17. [DOI: 10.1016/j.metabol.2014.01.011] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 14.6] [Reference Citation Analysis]
325 de Castro GS, Calder PC. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clinical Nutrition 2018;37:37-55. [DOI: 10.1016/j.clnu.2017.01.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 18.3] [Reference Citation Analysis]
326 Ochoa‐allemant P, Ezaz G, Trivedi HD, Sanchez‐fernandez L, Bonder A. Long‐term outcomes after liver transplantation in the Hispanic population. Liver Int 2020;40:437-46. [DOI: 10.1111/liv.14248] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
327 Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology 2017;67:1265-73. [DOI: 10.1016/j.jhep.2017.07.027] [Cited by in Crossref: 332] [Cited by in F6Publishing: 287] [Article Influence: 83.0] [Reference Citation Analysis]
328 Aso Y, Kato K, Sakurai S, Kishi H, Shimizu M, Jojima T, Iijima T, Maejima Y, Shimomura K, Usui I. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase‐4 in patients with type 2 diabetes and non‐alcoholic fatty liver disease. Int J Clin Pract 2019;73:e13335. [DOI: 10.1111/ijcp.13335] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
329 Dumas M, Kinross J, Nicholson JK. Metabolic Phenotyping and Systems Biology Approaches to Understanding Metabolic Syndrome and Fatty Liver Disease. Gastroenterology 2014;146:46-62. [DOI: 10.1053/j.gastro.2013.11.001] [Cited by in Crossref: 115] [Cited by in F6Publishing: 94] [Article Influence: 16.4] [Reference Citation Analysis]
330 Rodriguez B, Torres DM, Harrison SA. Physical activity: an essential component of lifestyle modification in NAFLD. Nat Rev Gastroenterol Hepatol 2012;9:726-31. [PMID: 23090329 DOI: 10.1038/nrgastro.2012.200] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
331 Mojtahed A, Kelly CJ, Herlihy AH, Kin S, Wilman HR, McKay A, Kelly M, Milanesi M, Neubauer S, Thomas EL, Bell JD, Banerjee R, Harisinghani M. Reference range of liver corrected T1 values in a population at low risk for fatty liver disease-a UK Biobank sub-study, with an appendix of interesting cases. Abdom Radiol (NY). 2019;44:72-84. [PMID: 30032383 DOI: 10.1007/s00261-018-1701-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
332 Wei CC, Luo Z, Hogstrand C, Xu YH, Wu LX, Chen GH, Pan YX, Song YF. Zinc reduces hepatic lipid deposition and activates lipophagy via Zn2+/MTF-1/PPARα and Ca2+/CaMKKβ/AMPK pathways. FASEB J 2018;:fj201800463. [PMID: 29912588 DOI: 10.1096/fj.201800463] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 12.7] [Reference Citation Analysis]
333 Asgari-Taee F, Zerafati-Shoae N, Dehghani M, Sadeghi M, Baradaran HR, Jazayeri S. Association of sugar sweetened beverages consumption with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Nutr 2019;58:1759-69. [PMID: 29761318 DOI: 10.1007/s00394-018-1711-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
334 Grebely J, Talwalkar JA. Recognizing and preventing death from compensated cirrhosis in the community. Liver Int 2012;32:2-4. [PMID: 22098367 DOI: 10.1111/j.1478-3231.2011.02627.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
335 Siebers N, Palmer M, Silberg DG, Jennings L, Bliss C, Martin PT. Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study. Eur J Drug Metab Pharmacokinet 2018;43:91-101. [PMID: 28702877 DOI: 10.1007/s13318-017-0429-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
336 Cho Y, Tokuhara D, Morikawa H, Kuwae Y, Hayashi E, Hirose M, Hamazaki T, Tanaka A, Kawamura T, Kawada N. Transient Elastography-Based Liver Profiles in a Hospital-Based Pediatric Population in Japan. PLoS One. 2015;10:e0137239. [PMID: 26398109 DOI: 10.1371/journal.pone.0137239] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
337 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5:211-8. [PMID: 25018867 DOI: 10.1136/flgastro-2013-100403] [Cited by in Crossref: 135] [Cited by in F6Publishing: 118] [Article Influence: 16.9] [Reference Citation Analysis]
338 Jiang ZG, Robson SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res. 2013;27:1-13. [PMID: 23554788 DOI: 10.7555/jbr.27.20120077] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
339 Shiga T, Shimbo T, Yoshizawa A. Multicenter investigation of lifestyle-related diseases and visceral disorders in thalidomide embryopathy at around 50 years of age. Birth Defects Res A Clin Mol Teratol 2015;103:787-93. [PMID: 26033770 DOI: 10.1002/bdra.23363] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
340 Golabi P, Stepanova M, Pham HT, Cable R, Rafiq N, Bush H, Gogoll T, Younossi ZM. Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). BMJ Open Gastroenterol 2018;5:e000198. [PMID: 29607054 DOI: 10.1136/bmjgast-2018-000198] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
341 Caballería L, Arteaga I, Pera G, Rodríguez L, Alumà A, Auladell MA, Torán P. [Risk factors associated with non-alcoholic fatty liver disease: a case-control study]. Med Clin (Barc) 2013;141:233-9. [PMID: 23601740 DOI: 10.1016/j.medcli.2012.11.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
342 Grattagliano I, Ubaldi E, Napoli L, Marulli CF, Nebiacolombo C, Cottone C, Portincasa P. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The “VARES” Italian multicenter study. Annals of Hepatology 2013;12:70-7. [DOI: 10.1016/s1665-2681(19)31387-0] [Cited by in Crossref: 12] [Article Influence: 1.5] [Reference Citation Analysis]
343 Harrison SA, Dennis A, Fiore MM, Kelly MD, Kelly CJ, Paredes AH, Whitehead JM, Neubauer S, Traber PG, Banerjee R. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. PLoS One 2018;13:e0203054. [PMID: 30192782 DOI: 10.1371/journal.pone.0203054] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
344 Xiang M, Wang PX, Wang AB, Zhang XJ, Zhang Y, Zhang P, Mei FH, Chen MH, Li H. Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. J Hepatol. 2016;64:1365-1377. [PMID: 26860405 DOI: 10.1016/j.jhep.2016.02.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 16.0] [Reference Citation Analysis]
345 Denkmayr L, Feldman A, Stechemesser L, Eder SK, Zandanell S, Schranz M, Strasser M, Huber-Schönauer U, Buch S, Hampe J, Paulweber B, Lackner C, Haufe H, Sotlar K, Datz C, Aigner E. Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients. J Clin Med 2018;7:E562. [PMID: 30562976 DOI: 10.3390/jcm7120562] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
346 Zhang TS, Qin HL, Wang T, Li HT, Li H, Xia SH, Xiang XH. Global publication trends and research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic review. Springerplus. 2015;4:776. [PMID: 26697286 DOI: 10.1186/s40064-015-1542-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
347 Liu Y, Song H, Wang L, Xu H, Shu X, Zhang L, Li Y, Li D, Ji G. Hepatoprotective and antioxidant activities of extracts from Salvia-Nelumbinis naturalis against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet in mice. J Transl Med 2014;12:315. [PMID: 25406833 DOI: 10.1186/s12967-014-0315-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
348 Tai FW, Syn WK, Alazawi W. Practical approach to non-alcoholic fatty liver disease in patients with diabetes. Diabet Med. 2015; Feb 12. [Epub ahead of print]. [PMID: 25683343 DOI: 10.1111/dme.12725] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
349 Park H, Dawwas GK, Liu X, Nguyen MH. Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study. J Intern Med. 2019;286:711-722. [PMID: 31359543 DOI: 10.1111/joim.12964] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
350 Lin HY, Wang FS, Yang YL, Huang YH. MicroRNA-29a Suppresses CD36 to Ameliorate High Fat Diet-Induced Steatohepatitis and Liver Fibrosis in Mice. Cells 2019;8:E1298. [PMID: 31652636 DOI: 10.3390/cells8101298] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
351 Taibbi A, Petta S, Matranga D, Caruana G, Cannella R, Busè G, Marco VD, Midiri M, Bartolotta TV. Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography. Ultrasonography 2021;40:407-16. [PMID: 33561928 DOI: 10.14366/usg.20147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
352 Kim Y, Ejaz A, Tayal A, Spolverato G, Bridges JF, Anders RA, Pawlik TM. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer 2014;120:3058-65. [PMID: 24917245 DOI: 10.1002/cncr.28843] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
353 Li M, Reynolds CM, Segovia SA, Gray C, Vickers MH. Developmental Programming of Nonalcoholic Fatty Liver Disease: The Effect of Early Life Nutrition on Susceptibility and Disease Severity in Later Life. Biomed Res Int 2015;2015:437107. [PMID: 26090409 DOI: 10.1155/2015/437107] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
354 Herrema H, Zhou Y, Zhang D, Lee J, Salazar Hernandez MA, Shulman GI, Ozcan U. XBP1s Is an Anti-lipogenic Protein. J Biol Chem 2016;291:17394-404. [PMID: 27325692 DOI: 10.1074/jbc.M116.728949] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 8.6] [Reference Citation Analysis]
355 Bouziana SD, Tziomalos K. Inhibition of apoptosis in the management of nonalcoholic fatty liver disease. World J Gastrointest Pharmacol Ther. 2013;4:4-8. [PMID: 23516172 DOI: 10.4292/wjgpt.v4.i1.4] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
356 Parker R, Oo YH, Adams DH. Management of patients with difficult autoimmune hepatitis. Therap Adv Gastroenterol. 2012;5:421-437. [PMID: 23152735 DOI: 10.1177/1756283X12450251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
357 Wang Z, Xu M, Hu Z, Hultström M, Lai E. Sex-specific prevalence of fatty liver disease and associated metabolic factors in Wuhan, south central China. Eur J Gastroenterol Hepatol 2014;26:1015-21. [PMID: 25003744 DOI: 10.1097/MEG.0000000000000151] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
358 Cheng YW, Chen KW, Kuo HC, Kuo CH, Lin WH, Chen PJ, Yeh SH. Specific diacylglycerols generated by hepatic lipogenesis stimulate the oncogenic androgen receptor activity in male hepatocytes. Int J Obes (Lond) 2019;43:2469-79. [PMID: 31455870 DOI: 10.1038/s41366-019-0431-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
359 Mazidi M, Katsiki N, Mikhailidis DP, Banach M. Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic survey. Atherosclerosis 2019;284:129-35. [PMID: 30878840 DOI: 10.1016/j.atherosclerosis.2018.11.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
360 Golabi P, Paik J, Reddy R, Bugianesi E, Trimble G, Younossi ZM. Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. BMC Gastroenterol. 2019;19:56. [PMID: 30991959 DOI: 10.1186/s12876-019-0972-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
361 Keyhani-nejad F, Irmler M, Isken F, Wirth EK, Beckers J, Birkenfeld AL, Pfeiffer AFH. Nutritional strategy to prevent fatty liver and insulin resistance independent of obesity by reducing glucose-dependent insulinotropic polypeptide responses in mice. Diabetologia 2015;58:374-83. [DOI: 10.1007/s00125-014-3423-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
362 Fielding CM, Angulo P. Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep 2014;13:151-8. [PMID: 24977111 DOI: 10.1007/s11901-014-0227-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
363 Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Review of Gastroenterology & Hepatology 2014;5:189-200. [DOI: 10.1586/egh.11.21] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
364 Ranadive SM, Lofrano-Porto A, Soares EMKVK, Eagan L, Porto LGG, Smith DL. Low testosterone and cardiometabolic risks in a real-world study of US male firefighters. Sci Rep 2021;11:14189. [PMID: 34244582 DOI: 10.1038/s41598-021-93603-z] [Reference Citation Analysis]
365 D'Adamo E, Castorani V, Nobili V. The Liver in Children With Metabolic Syndrome. Front Endocrinol (Lausanne) 2019;10:514. [PMID: 31428049 DOI: 10.3389/fendo.2019.00514] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
366 Pereira K, Salsamendi J, Casillas J. The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci 2015;5:32. [PMID: 26167390 DOI: 10.4103/2156-7514.157860] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
367 Nakamura N, Hatano E, Iguchi K, Sato M, Kawaguchi H, Ohtsu I, Sakurai T, Aizawa N, Iijima H, Nishiguchi S, Tomono T, Okuda Y, Wada S, Seo S, Taura K, Uemoto S, Ikegawa M. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study. BMC Cancer 2019;19:621. [PMID: 31238892 DOI: 10.1186/s12885-019-5825-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
368 Yuan JM, Grouls M, Carmella SG, Wang R, Heskin A, Jiang Y, Tan YT, Adams-Haduch J, Gao YT, Hecht SS. Prediagnostic levels of urinary 8-epi-prostaglandin F2α and prostaglandin E2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma. Carcinogenesis 2019;40:989-97. [PMID: 30615102 DOI: 10.1093/carcin/bgy180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
369 Khullar V, Dolganiuc A, Firpi RJ. Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease. World J Transplant 2014;4:81-92. [PMID: 25032097 DOI: 10.5500/wjt.v4.i2.81] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
370 Zhuang A, Yap FY, Bruce C, Leung C, Plan MR, Sullivan MA, Herath C, McCarthy D, Sourris KC, Kantharidis P, Coughlan MT, Febbraio MA, Hodson MP, Watt MJ, Angus P, Schulz BL, Forbes JM. Increased liver AGEs induce hepatic injury mediated through an OST48 pathway. Sci Rep 2017;7:12292. [PMID: 28947796 DOI: 10.1038/s41598-017-12548-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
371 Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412-425. [PMID: 27273168 DOI: 10.1038/nrgastro.2016.85] [Cited by in Crossref: 362] [Cited by in F6Publishing: 302] [Article Influence: 72.4] [Reference Citation Analysis]
372 Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis 2016;20:293-312. [PMID: 27063270 DOI: 10.1016/j.cld.2015.10.011] [Cited by in Crossref: 111] [Cited by in F6Publishing: 85] [Article Influence: 18.5] [Reference Citation Analysis]
373 Corey KE, Kaplan LM. Obesity and Liver Disease. Clinics in Liver Disease 2014;18:1-18. [DOI: 10.1016/j.cld.2013.09.019] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 10.7] [Reference Citation Analysis]
374 Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32:22-29. [PMID: 22418885 DOI: 10.1055/s-0032-1306423] [Cited by in Crossref: 122] [Cited by in F6Publishing: 105] [Article Influence: 13.6] [Reference Citation Analysis]
375 Arias-Loste MT, Iruzubieta P, Crespo J. Paediatric non-alcoholic fatty liver disease: a more complex disease than in the adulthood? Hepatobiliary Surg Nutr 2019;8:270-3. [PMID: 31245411 DOI: 10.21037/hbsn.2018.12.16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
376 Ibrahim SH, Hirsova P, Malhi H, Gores GJ. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci 2016;61:1325-36. [PMID: 26626909 DOI: 10.1007/s10620-015-3977-1] [Cited by in Crossref: 111] [Cited by in F6Publishing: 99] [Article Influence: 18.5] [Reference Citation Analysis]
377 Agrawal S, Duseja AK. Non-alcoholic Fatty Liver Disease: East Versus West. J Clin Exp Hepatol 2012;2:122-34. [PMID: 25755421 DOI: 10.1016/S0973-6883(12)60101-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
378 Inayat F, Ur Rahman Z, Hurairah A. Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Cureus 2016;8:e754. [PMID: 27733959 DOI: 10.7759/cureus.754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
379 Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease. Journal of Clinical Gastroenterology 2012;46:272-84. [DOI: 10.1097/mcg.0b013e31824587e0] [Cited by in Crossref: 80] [Cited by in F6Publishing: 25] [Article Influence: 8.9] [Reference Citation Analysis]
380 Fujikawa H, Sakamoto Y, Masuda N, Oniki K, Kamei S, Nohara H, Nakashima R, Maruta K, Kawakami T, Eto Y, Takahashi N, Takeo T, Nakagata N, Watanabe H, Otake K, Ogata Y, Tomioka NH, Hosoyamada M, Takada T, Ueno-Shuto K, Suico MA, Kai H, Saruwatari J, Shuto T. Higher Blood Uric Acid in Female Humans and Mice as a Protective Factor against Pathophysiological Decline of Lung Function. Antioxidants (Basel) 2020;9:E387. [PMID: 32384764 DOI: 10.3390/antiox9050387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
381 Doycheva I, Patel N, Peterson M, Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J Diabetes Complications. 2013;27:293-300. [PMID: 23312215 DOI: 10.1016/j.jdiacomp.2012.10.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
382 Fierbinteanu-Braticevici C, Sinescu C, Moldoveanu A, Petrisor A, Diaconu S, Cretoiu D, Braticevici B. Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health. Cell Biol Toxicol 2017;33:5-14. [PMID: 27680752 DOI: 10.1007/s10565-016-9361-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
383 Thompson MD, Cismowski MJ, Trask AJ, Lallier SW, Graf AE, Rogers LK, Lucchesi PA, Brigstock DR. Enhanced Steatosis and Fibrosis in Liver of Adult Offspring Exposed to Maternal High-Fat Diet. Gene Expr 2016;17:47-59. [PMID: 27342733 DOI: 10.3727/105221616X692135] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
384 Puppala J, Siddapuram SP, Akka J, Munshi A. Genetics of nonalcoholic Fatty liver disease: an overview. J Genet Genomics. 2013;40:15-22. [PMID: 23357341 DOI: 10.1016/j.jgg.2012.12.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
385 Torres do Rego A, Perez de Isla L, Saltijeral Cerezo A, Vitale G, Izarra A, Alvarez-sala Walther LA. Cholesterol control according to the presence of metabolic syndrome in coronary and diabetic patients. Relationship with non-alcoholic fatty liver disease. European Journal of Internal Medicine 2014;25:438-43. [DOI: 10.1016/j.ejim.2014.03.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
386 Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM, Abumrad NN, Flynn CR. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309:G270-G278. [PMID: 26113297 DOI: 10.1152/ajpgi.00304.2014] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 18.3] [Reference Citation Analysis]
387 Noureddin M, Loomba R. Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers. Clin Liver Dis (Hoboken) 2012;1:104-7. [PMID: 31186861 DOI: 10.1002/cld.65] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
388 Hyysalo J, Männistö VT, Zhou Y, Arola J, Kärjä V, Leivonen M, Juuti A, Jaser N, Lallukka S, Käkelä P. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol. 2014;60:839-846. [PMID: 24333862 DOI: 10.1016/j.jhep.2013.12.009] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 9.5] [Reference Citation Analysis]
389 Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol. 2012;9:372-381. [PMID: 22565095 DOI: 10.1038/nrgastro.2012.79] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 8.6] [Reference Citation Analysis]
390 Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M, Haufe W, Hooker C, Yin M, Ehman R, Lin GY, Valasek MA, Brenner DA, Richards L; San Diego Integrated NAFLD Research Consortium (SINC). Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61:1239-1250. [PMID: 25482832 DOI: 10.1002/hep.27647] [Cited by in Crossref: 216] [Cited by in F6Publishing: 195] [Article Influence: 36.0] [Reference Citation Analysis]
391 Hannah WN, Harrison SA. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1365-1374. [PMID: 27052013 DOI: 10.1007/s10620-016-4153-y] [Cited by in Crossref: 63] [Cited by in F6Publishing: 46] [Article Influence: 12.6] [Reference Citation Analysis]
392 Ming J, Xu S, Gao B, Liu G, Ji Y, Yang F, Jia Y, Fang Y, Ji Q. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi’an, China: a five-year cohort study. Liver Int. 2015;Epub ahead of print. [PMID: 25879672 DOI: 10.1111/liv.12851] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
393 Likhitsup A, Dundulis J, Ansari S, El-Halawany H, Michelson R, Hutton C, Kennedy K, Helzberg JH, Chhabra R. Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department. Ann Gastroenterol. 2019;32:283-286. [PMID: 31040626 DOI: 10.20524/aog.2019.0371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
394 Lyall MJ, Thomson JP, Cartier J, Ottaviano R, Kendall TJ, Meehan RR, Drake AJ. Non-alcoholic fatty liver disease (NAFLD) is associated with dynamic changes in DNA hydroxymethylation. Epigenetics 2020;15:61-71. [PMID: 31389294 DOI: 10.1080/15592294.2019.1649527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
395 Katzka DA, Loftus EV Jr, Camilleri M. Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases. Clin Pharmacol Ther 2012;92:306-20. [PMID: 22828717 DOI: 10.1038/clpt.2012.77] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
396 Borges KA, Dai J, Parikh ND, Schwartz M, Nguyen MH, Roberts LR, Befeler AS, Srivastava S, Rinaudo JA, Feng Z, Marrero JA, Reddy KR. Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network. Contemp Clin Trials 2019;76:49-54. [PMID: 30439517 DOI: 10.1016/j.cct.2018.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
397 Stine JG, Rinella ME. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol 2017;112:752-4. [PMID: 28469217 DOI: 10.1038/ajg.2017.60] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
398 Lin YC, Lian IB, Kor CT, Chang CC, Su PY, Chang WT, Liang YF, Su WW, Soon MS. Association between soil heavy metals and fatty liver disease in men in Taiwan: a cross sectional study. BMJ Open 2017;7:e014215. [PMID: 28115335 DOI: 10.1136/bmjopen-2016-014215] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
399 Wilman HR, Kelly M, Garratt S, Matthews PM, Milanesi M, Herlihy A, Gyngell M, Neubauer S, Bell JD, Banerjee R, Thomas EL. Characterisation of liver fat in the UK Biobank cohort. PLoS One. 2017;12:e0172921. [PMID: 28241076 DOI: 10.1371/journal.pone.0172921] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 10.5] [Reference Citation Analysis]
400 Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN). Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38:134-143. [PMID: 23718573 DOI: 10.1111/apt.12352] [Cited by in Crossref: 113] [Cited by in F6Publishing: 97] [Article Influence: 14.1] [Reference Citation Analysis]
401 Tian J, Zhong R, Liu C, Tang Y, Gong J, Chang J, Lou J, Ke J, Li J, Zhang Y, Yang Y, Zhu Y, Gong Y, Xu Y, Liu P, Yu X, Xiao L, Du M, Yang L, Yuan J, Wang Y, Chen W, Wei S, Liang Y, Zhang X, He M, Wu T, Yao P, Miao X. Association between bilirubin and risk of Non-Alcoholic Fatty Liver Disease based on a prospective cohort study. Sci Rep 2016;6:31006. [PMID: 27484402 DOI: 10.1038/srep31006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
402 Tarquini R, Mazzoccoli G. Clock Genes, Metabolism, and Cardiovascular Risk. Heart Fail Clin 2017;13:645-55. [PMID: 28865774 DOI: 10.1016/j.hfc.2017.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
403 Wahlang B, Appana S, Falkner KC, McClain CJ, Brock G, Cave MC. Insecticide and metal exposures are associated with a surrogate biomarker for non-alcoholic fatty liver disease in the National Health and Nutrition Examination Survey 2003-2004. Environ Sci Pollut Res Int 2020;27:6476-87. [PMID: 31873887 DOI: 10.1007/s11356-019-07066-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
404 Friedrich-Rust M, Romen D, Vermehren J, Kriener S, Sadet D, Herrmann E, Zeuzem S, Bojunga J. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol. 2012;81:e325-e331. [PMID: 22119555 DOI: 10.1016/j.ejrad.2011.10.029] [Cited by in Crossref: 129] [Cited by in F6Publishing: 112] [Article Influence: 12.9] [Reference Citation Analysis]
405 Austin P, Gerber L, Paik JM, Price JK, Escheik C, Younossi ZM. Aerobic capacity and exercise performance in nonalcoholic fatty liver disease. J Sports Med Phys Fitness 2019;59. [DOI: 10.23736/s0022-4707.19.09231-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
406 Dowman JK, Hopkins LJ, Reynolds GM, Armstrong MJ, Nasiri M, Nikolaou N, van Houten EL, Visser JA, Morgan SA, Lavery GG. Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology. 2013;154:4536-4547. [PMID: 24080367 DOI: 10.1210/en.2013-1592] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
407 Richter LR, Wan Q, Wen D, Zhang Y, Yu J, Kang JK, Zhu C, McKinnon EL, Gu Z, Qiang L, Pajvani UB. Targeted Delivery of Notch Inhibitor Attenuates Obesity-Induced Glucose Intolerance and Liver Fibrosis. ACS Nano 2020;14:6878-86. [PMID: 32441510 DOI: 10.1021/acsnano.0c01007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
408 Josan S, Billingsley K, Orduna J, Park JM, Luong R, Yu L, Hurd R, Pfefferbaum A, Spielman D, Mayer D. Assessing inflammatory liver injury in an acute CCl4 model using dynamic 3D metabolic imaging of hyperpolarized [1-(13)C]pyruvate. NMR Biomed. 2015;28:1671-1677. [PMID: 26474216 DOI: 10.1002/nbm.3431] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
409 Doycheva I, Loomba R. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Adv Ther. 2014;31:30-43. [PMID: 24385405 DOI: 10.1007/s12325-013-0084-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
410 Cherkashchenko NA, Livzan MA, Krolevets TS. [Clinical features of the comorbid course of non-alcoholic fatty liver disease and gallstone disease]. Ter Arkh 2020;92:29-36. [PMID: 33346459 DOI: 10.26442/00403660.2020.08.000764] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
411 Siddiqui MS, Sterling RK, Luketic VA, Puri P, Stravitz RT, Bouneva I, Boyett S, Fuchs M, Sargeant C, Warnick GR, Grami S, Sanyal AJ. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 2013;145:1271-9.e1-3. [PMID: 23973920 DOI: 10.1053/j.gastro.2013.08.036] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
412 Nishi T, Babazono A, Maeda T, Imatoh T, Une H. Effects of Eating Fast and Eating Before Bedtime on the Development of Nonalcoholic Fatty Liver Disease. Population Health Management 2016;19:279-83. [DOI: 10.1089/pop.2015.0088] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
413 Tang Z, Pham M, Hao Y, Wang F, Patel D, Jean-Baptiste L, Fan L, Wang W, Wang Y, Cheng F. Sex, Age, and BMI Modulate the Association of Physical Examinations and Blood Biochemistry Parameters and NAFLD: A Retrospective Study on 1994 Cases Observed at Shuguang Hospital, China. Biomed Res Int 2019;2019:1246518. [PMID: 31341886 DOI: 10.1155/2019/1246518] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
414 Wahlang B, Falkner KC, Clair HB, Al-Eryani L, Prough RA, States JC, Coslo DM, Omiecinski CJ, Cave MC. Human receptor activation by aroclor 1260, a polychlorinated biphenyl mixture. Toxicol Sci 2014;140:283-97. [PMID: 24812009 DOI: 10.1093/toxsci/kfu083] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
415 Ayoub F, Trillo-Alvarez C, Morelli G, Lascano J. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. World J Hepatol. 2018;10:34-40. [PMID: 29399276 DOI: 10.4254/wjh.v10.i1.34] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
416 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch. 2011;458:511-523. [PMID: 21442288 DOI: 10.1007/s00428-011-1066-1].] [Reference Citation Analysis]
417 Zhai HL, Wang NJ, Han B, Li Q, Chen Y, Zhu CF, Chen YC, Xia FZ, Cang Z, Zhu CX, Lu M, Lu YL. Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: A cross-sectional study (Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China)). Br J Nutr. 2016;115:1352-1359. [PMID: 26888280 DOI: 10.1017/s0007114516000386] [Cited by in Crossref: 39] [Cited by in F6Publishing: 19] [Article Influence: 7.8] [Reference Citation Analysis]
418 Ahn J, Lee H, Jung CH, Ha T. Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol Nutr Food Res. 2012;56:1665-1674. [PMID: 22968990 DOI: 10.1002/mnfr.201200182] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 8.4] [Reference Citation Analysis]
419 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 25.5] [Reference Citation Analysis]
420 El-Gohary M, Moore M, Roderick P, Watkins E, Dash J, Reinson T, Newell C, Kim M, Stuart B, Becque T, Sheron N. Local care and treatment of liver disease (LOCATE) - A cluster-randomized feasibility study to discover, assess and manage early liver disease in primary care. PLoS One 2018;13:e0208798. [PMID: 30576330 DOI: 10.1371/journal.pone.0208798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
421 Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver. 2012;6:149-171. [PMID: 22570745 DOI: 10.5009/gnl.2012.6.2.149] [Cited by in Crossref: 247] [Cited by in F6Publishing: 219] [Article Influence: 27.4] [Reference Citation Analysis]
422 Nagashimada M, Honda M. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. Int J Mol Sci 2021;22:8008. [PMID: 34360773 DOI: 10.3390/ijms22158008] [Reference Citation Analysis]
423 Tiwari-Heckler S, Gan-Schreier H, Stremmel W, Chamulitrat W, Pathil A. Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors. Nutrients. 2018;10. [PMID: 29883377 DOI: 10.3390/nu10050649] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
424 Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013;19:6969-78. [PMID: 24222941 DOI: 10.3748/wjg.v19.i41.6969] [Cited by in CrossRef: 135] [Cited by in F6Publishing: 128] [Article Influence: 19.3] [Reference Citation Analysis]
425 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32-42. [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147] [Cited by in Crossref: 329] [Cited by in F6Publishing: 275] [Article Influence: 65.8] [Reference Citation Analysis]
426 Lin SC, Ang B, Hernandez C, Bettencourt R, Jain R, Salotti J, Richards L, Kono Y, Bhatt A, Aryafar H. Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial. Therap Adv Gastroenterol. 2016;9:152-161. [PMID: 26929777 DOI: 10.1177/1756283x15621232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
427 Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1. [DOI: 10.1038/nrdp.2015.80] [Cited by in Crossref: 302] [Cited by in F6Publishing: 258] [Article Influence: 50.3] [Reference Citation Analysis]
428 Caussy C, Alquiraish MH, Nguyen P, Hernandez C, Cepin S, Fortney LE, Ajmera V, Bettencourt R, Collier S, Hooker J, Sy E, Rizo E, Richards L, Sirlin CB, Loomba R. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67:1348-1359. [PMID: 29108123 DOI: 10.1002/hep.29639] [Cited by in Crossref: 108] [Cited by in F6Publishing: 92] [Article Influence: 36.0] [Reference Citation Analysis]
429 Yoon CY, Lee M, Kim SU, Lim H, Chang TI, Kee YK, Han SG, Han IM, Kwon YE, Park KS, Lee MJ, Park JT, Han SH, Ahn SH, Kang SW, Yoo TH. Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study. Kidney Res Clin Pract 2017;36:48-57. [PMID: 28392997 DOI: 10.23876/j.krcp.2017.36.1.48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
430 Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180-190. [PMID: 27646933 DOI: 10.1136/gutjnl-2016-312431] [Cited by in Crossref: 214] [Cited by in F6Publishing: 197] [Article Influence: 42.8] [Reference Citation Analysis]
431 Zhang Q, Niu X, Tian L, Liu J, Niu R, Quan J, Yu J, Lin W, Qian Z, Zeng P. CTRP13 attenuates the expression of LN and CAV-1 Induced by high glucose via CaMKKβ/AMPK pathway in rLSECs. Aging (Albany NY) 2020;12:11485-99. [PMID: 32554851 DOI: 10.18632/aging.103234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
432 Saltzman ET, Palacios T, Thomsen M, Vitetta L. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. Front Microbiol 2018;9:61. [PMID: 29441049 DOI: 10.3389/fmicb.2018.00061] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 21.3] [Reference Citation Analysis]
433 Zhang Y, Xu J, Wang X, Ren X, Liu Y. Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. BMC Genomics 2019;20:862. [PMID: 31726978 DOI: 10.1186/s12864-019-6251-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
434 Hamid H, Zhang JY, Li WX, Liu C, Li ML, Zhao LH, Ji C, Ma QG. Interactions between the cecal microbiota and non-alcoholic steatohepatitis using laying hens as the model. Poult Sci 2019;98:2509-21. [PMID: 30690636 DOI: 10.3382/ps/pey596] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
435 Cao Y, Wang C, Liu J, Liu ZM, Ling WH, Chen YM. Greater serum carotenoid levels associated with lower prevalence of nonalcoholic fatty liver disease in Chinese adults. Sci Rep 2015;5:12951. [PMID: 26256414 DOI: 10.1038/srep12951] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
436 Sabag A, Little JP, Johnson NA. Low-volume high-intensity interval training for cardiometabolic health. J Physiol 2021. [PMID: 33760255 DOI: 10.1113/JP281210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
437 Chen S, Zhao X, Wan J, Ran L, Qin Y, Wang X, Gao Y, Shu F, Zhang Y, Liu P, Zhang Q, Zhu J, Mi M. Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial. Pharmacol Res. 2015;99:74-81. [PMID: 26032587 DOI: 10.1016/j.phrs.2015.05.009] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 16.5] [Reference Citation Analysis]
438 Jiang ZG, Mukamal K, Tapper E, Robson SC, Tsugawa Y. Low LDL-C and high HDL-C levels are associated with elevated serum transaminases amongst adults in the United States: a cross-sectional study. PLoS One 2014;9:e85366. [PMID: 24454851 DOI: 10.1371/journal.pone.0085366] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
439 Stadlmayr A, Aigner E, Steger B, Scharinger L, Lederer D, Mayr A, Strasser M, Brunner E, Heuberger A, Hohla F. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med. 2011;270:41-49. [PMID: 21414047 DOI: 10.1111/j.1365-2796.2011.02377.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 7.6] [Reference Citation Analysis]
440 Ma J, Hennein R, Liu C, Long MT, Hoffmann U, Jacques PF, Lichtenstein AH, Hu FB, Levy D. Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. Gastroenterology 2018;155:107-17. [PMID: 29604292 DOI: 10.1053/j.gastro.2018.03.038] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 18.3] [Reference Citation Analysis]
441 Brown PM, Rotman Y. What if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liver. Gut 2017;66:1732-3. [PMID: 28274997 DOI: 10.1136/gutjnl-2017-313712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
442 Waskowicz LR, Zhou J, Landau DJ, Brooks ED, Lim A, Yavarow ZA, Kudo T, Zhang H, Wu Y, Grant S, Young SP, Huat BB, Yen PM, Koeberl DD. Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia. Hum Mol Genet 2019;28:143-54. [PMID: 30256948 DOI: 10.1093/hmg/ddy343] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
443 Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int. 2014;34:1250-1258. [PMID: 24267865 DOI: 10.1111/liv.12379] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
444 Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Current Opinion in Infectious Diseases 2012;25:10-6. [DOI: 10.1097/qco.0b013e32834ef599] [Cited by in Crossref: 49] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
445 Tripodi A, Fracanzani AL, Primignani M, Chantarangkul V, Clerici M, Mannucci PM, Peyvandi F, Bertelli C, Valenti L, Fargion S. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;61:148-154. [PMID: 24657400 DOI: 10.1016/j.jhep.2014.03.013] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 12.1] [Reference Citation Analysis]
446 Morsy MD, Aboonq MS, ALsleem MA, Abusham AA. Taurine prevents high-fat diet-induced-hepatic steatosis in rats by direct inhibition of hepatic sterol regulatory element-binding proteins and activation of AMPK. Clin Exp Pharmacol Physiol 2020. [PMID: 32691860 DOI: 10.1111/1440-1681.13387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
447 Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Savides MT, Alquiraish MH, Valasek MA, Rizo E, Richards L, Brenner D, Sirlin CB, Loomba R. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. Gastroenterology 2017; 152: 598-607. e2. [PMID: 27911262 DOI: 10.1053/j.gastro.2016.10.026] [Cited by in Crossref: 274] [Cited by in F6Publishing: 230] [Article Influence: 54.8] [Reference Citation Analysis]
448 Kapuria D, Takyar VK, Etzion O, Surana P, O'Keefe JH, Koh C. Association of Hepatic Steatosis With Subclinical Atherosclerosis: Systematic Review and Meta-Analysis. Hepatol Commun 2018;2:873-83. [PMID: 30094399 DOI: 10.1002/hep4.1199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
449 Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, Seki E, Sirlin CB, Loomba R. Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterol Res Pract 2013;2013:498296. [PMID: 24348536 DOI: 10.1155/2013/498296] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
450 Wei J, Lei GH, Fu L, Zeng C, Yang T, Peng SF. Association between Dietary Vitamin C Intake and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study among Middle-Aged and Older Adults. PLoS One 2016;11:e0147985. [PMID: 26824361 DOI: 10.1371/journal.pone.0147985] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
451 Akinkugbe AA, Slade GD, Barritt AS, Cole SR, Offenbacher S, Petersmann A, Kocher T, Lerch MM, Mayerle J, Völzke H, Heiss G, Holtfreter B. Periodontitis and Non-alcoholic Fatty Liver Disease, a population-based cohort investigation in the Study of Health in Pomerania. J Clin Periodontol 2017;44:1077-87. [PMID: 28804947 DOI: 10.1111/jcpe.12800] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
452 Gou XJ, Gao S, Chen L, Feng Q, Hu YY. A Metabolomic Study on the Intervention of Traditional Chinese Medicine Qushi Huayu Decoction on Rat Model of Fatty Liver Induced by High-Fat Diet. Biomed Res Int 2019;2019:5920485. [PMID: 30881991 DOI: 10.1155/2019/5920485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
453 Bian Z, Ma X. Liver fibrogenesis in non-alcoholic steatohepatitis. Front Physiol 2012;3:248. [PMID: 22934006 DOI: 10.3389/fphys.2012.00248] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
454 Martins E, Oliveira A. NAFLD and cardiovascular disease. Porto Biomed J 2018;3:e2. [PMID: 31595238 DOI: 10.1016/j.pbj.0000000000000002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
455 Hirono H, Watanabe K, Hasegawa K, Kohno M, Terai S, Ohkoshi S. Impact of continuous positive airway pressure therapy for nonalcoholic fatty liver disease in patients with obstructive sleep apnea. World J Clin Cases 2021;9:5112-25. [PMID: 34307562 DOI: 10.12998/wjcc.v9.i19.5112] [Reference Citation Analysis]
456 Jablonski KL, Jovanovich A, Holmen J, Targher G, McFann K, Kendrick J, Chonchol M. Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2013;23:792-798. [PMID: 23415456 DOI: 10.1016/j.numecd.2012.12.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
457 Tsuji Y, Kaji K, Kitade M, Kaya D, Kitagawa K, Ozutsumi T, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Moriya K, Akahane T, Yoshiji H. Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. Microorganisms 2020;8:E925. [PMID: 32575352 DOI: 10.3390/microorganisms8060925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
458 Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, Collier J, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 2016;64:308-315. [PMID: 26471505 DOI: 10.1016/j.jhep.2015.10.009] [Cited by in Crossref: 116] [Cited by in F6Publishing: 100] [Article Influence: 19.3] [Reference Citation Analysis]
459 Hendy OM, Elsabaawy MM, Aref MM, Khalaf FM, Oda AMA, El Shazly HM. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease. APMIS 2017;125:607-13. [DOI: 10.1111/apm.12696] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
460 Ioannou GN, Haigh WG, Thorning D, Savard C. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J Lipid Res. 2013;54:1326-1334. [PMID: 23417738 DOI: 10.1194/jlr.m034876] [Cited by in Crossref: 109] [Cited by in F6Publishing: 68] [Article Influence: 13.6] [Reference Citation Analysis]
461 Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, Ortiz-Lopez C, Hecht J, Feldstein AE, Webb A, Louden C, Goros M, Tio F. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60:167-174. [PMID: 23973932 DOI: 10.1016/j.jhep.2013.07.042] [Cited by in Crossref: 154] [Cited by in F6Publishing: 130] [Article Influence: 19.3] [Reference Citation Analysis]
462 Hirode G, Vittinghoff E, Wong RJ. Increasing Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease Among Hospitalized Adults in the United States. J Clin Gastroenterol. 2019;53:765-771. [PMID: 31135632 DOI: 10.1097/mcg.0000000000001229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
463 Ratziu V, Voiculescu M, Poynard T. Touching some firm ground in the epidemiology of NASH. J Hepatol. 2012;56:23-25. [PMID: 21875499 DOI: 10.1016/j.jhep.2011.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
464 Wang L, Guo J, Lu J. Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females. Oncotarget 2016;7:35632-42. [PMID: 27248665 DOI: 10.18632/oncotarget.9691] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
465 Houben T, Oligschlaeger Y, Bitorina AV, Hendrikx T, Walenbergh SMA, Lenders MH, Gijbels MJJ, Verheyen F, Lütjohann D, Hofker MH, Binder CJ, Shiri-Sverdlov R. Blood-derived macrophages prone to accumulate lysosomal lipids trigger oxLDL-dependent murine hepatic inflammation. Sci Rep 2017;7:12550. [PMID: 28970532 DOI: 10.1038/s41598-017-13058-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
466 Dai H, Wang W, Chen R, Chen Z, Lu Y, Yuan H. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab (Lond). 2017;14:49. [PMID: 28775758 DOI: 10.1186/s12986-017-0206-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
467 Lykiardopoulos B, Hagström H, Fredrikson M, Ignatova S, Stål P, Hultcrantz R, Ekstedt M, Kechagias S. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. PLoS One 2016;11:e0167776. [PMID: 27936091 DOI: 10.1371/journal.pone.0167776] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
468 Acharya C, Dharel N, Sterling RK. Chronic liver disease in the human immunodeficiency virus patient. Clin Liver Dis 2015;19:1-22. [PMID: 25454294 DOI: 10.1016/j.cld.2014.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
469 Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? Hepatology. 2017;65:2090-2099. [PMID: 28100008 DOI: 10.1002/hep.29055] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 17.0] [Reference Citation Analysis]
470 Hydes T, Buchanan R, Kennedy OJ, Fraser S, Parkes J, Roderick P. Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease. BMJ Open 2020;10:e040970. [PMID: 32988952 DOI: 10.1136/bmjopen-2020-040970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
471 Ma H, Xu C, Xu L, Yu C, Miao M, Li Y. Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population. BMC Gastroenterol. 2013;13:3. [PMID: 23294935 DOI: 10.1186/1471-230x-13-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
472 Mazidi M, Kengne AP. Higher adherence to plant-based diets are associated with lower likelihood of fatty liver. Clinical Nutrition 2019;38:1672-7. [DOI: 10.1016/j.clnu.2018.08.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
473 Lim S, Taskinen MR, Borén J. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obes Rev 2019;20:599-611. [PMID: 30589487 DOI: 10.1111/obr.12820] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 10.7] [Reference Citation Analysis]
474 Sherif ZA, Saeed A, Ghavimi S, Nouraie SM, Laiyemo AO, Brim H, Ashktorab H. Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Dig Dis Sci. 2016;61:1214-1225. [PMID: 27038448 DOI: 10.1007/s10620-016-4143-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 16.6] [Reference Citation Analysis]
475 Dey G, Singh V, Dewangan J, Daniel PV, Kamthan M, Ghosh D, Mondal P, Ghosh S. Renal Clearable New NIR Probe: Precise Quantification of Albumin in Biofluids and Fatty Liver Disease State Identification through Tissue Specific High Contrast Imaging in Vivo. Anal Chem 2017;89:10343-52. [DOI: 10.1021/acs.analchem.7b02187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
476 Stephenson K, Kennedy L, Hargrove L, Demieville J, Thomson J, Alpini G, Francis H. Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights. Gene Expr. 2018;18:5-17. [PMID: 29096730 DOI: 10.3727/105221617x15093707969658] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
477 Dyson JK, Mcpherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013;66:1033-45. [DOI: 10.1136/jclinpath-2013-201620] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
478 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384-91. [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027] [Cited by in Crossref: 536] [Cited by in F6Publishing: 484] [Article Influence: 59.6] [Reference Citation Analysis]
479 Feng Q, Baker SS, Liu W, Arbizu RA, Aljomah G, Khatib M, Nugent CA, Baker RD, Forte TM, Hu Y, Zhu L. Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers. Pathology 2015;47:341-8. [PMID: 25938357 DOI: 10.1097/PAT.0000000000000251] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
480 Shi KQ, Fan YC, Liu WY, Li LF, Chen YP, Zheng MH. Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. Mol Biol Rep. 2012;39:9715-9722. [PMID: 22718512 DOI: 10.1007/s11033-012-1836-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
481 Lemasters JJ, Holmuhamedov EL, Czerny C, Zhong Z, Maldonado EN. Regulation of mitochondrial function by voltage dependent anion channels in ethanol metabolism and the Warburg effect. Biochim Biophys Acta. 2012;1818:1536-1544. [PMID: 22172804 DOI: 10.1016/j.bbamem.2011.11.034] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
482 Graffy PM, Pickhardt PJ. Quantification of hepatic and visceral fat by CT and MR imaging: relevance to the obesity epidemic, metabolic syndrome and NAFLD. Br J Radiol 2016;89:20151024. [PMID: 26876880 DOI: 10.1259/bjr.20151024] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
483 Kuo NC, Huang SY, Yang CY, Shen HH, Lee YM. Involvement of HO-1 and Autophagy in the Protective Effect of Magnolol in Hepatic Steatosis-Induced NLRP3 Inflammasome Activation In Vivo and In Vitro. Antioxidants (Basel) 2020;9:E924. [PMID: 32992548 DOI: 10.3390/antiox9100924] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
484 Teschke R, Wolff A, Eickhoff A, Danan G. Is obesity rather than the dietary supplement used for weight reduction the cause of liver injury? JGH Open 2018;2:152-7. [PMID: 30483581 DOI: 10.1002/jgh3.12057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
485 Hanke D, Zahradka P, Mohankumar SK, Clark JL, Taylor CG. A diet high in α-linolenic acid and monounsaturated fatty acids attenuates hepatic steatosis and alters hepatic phospholipid fatty acid profile in diet-induced obese rats. Prostaglandins Leukot Essent Fatty Acids. 2013;89:391-401. [PMID: 24140006 DOI: 10.1016/j.plefa.2013.09.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
486 Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, Urquhart B, Harvie R, Mckenzie C, Summers K, Reid G, Burton JP, Silverman M. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am J Gastroenterol 2020;115:1055-65. [DOI: 10.14309/ajg.0000000000000661] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 37.0] [Reference Citation Analysis]
487 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
488 Goodus MT, Carson KE, Sauerbeck AD, Dey P, Alfredo AN, Popovich PG, Bruno RS, McTigue DM. Liver inflammation at the time of spinal cord injury enhances intraspinal pathology, liver injury, metabolic syndrome and locomotor deficits. Exp Neurol 2021;342:113725. [PMID: 33933462 DOI: 10.1016/j.expneurol.2021.113725] [Reference Citation Analysis]
489 Lequoy M, Gigante E, Couty JP, Desbois-Mouthon C. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. Horm Mol Biol Clin Investig 2020;41:/j/hmbci. [PMID: 32112699 DOI: 10.1515/hmbci-2019-0044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
490 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
491 Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17. [PMID: 27213358 DOI: 10.3390/ijms17050774] [Cited by in Crossref: 248] [Cited by in F6Publishing: 215] [Article Influence: 49.6] [Reference Citation Analysis]
492 Moriyama K, Urata N, Masuda Y, Oda K, Okuno C, Yamada C, Takashimizu S, Kubo A, Kishimoto N, Nishizaki Y. Usefulness of Triglyceride to High-Density Lipoprotein Ratio and Alanine Aminotransferase for Predicting Insulin Resistance and Metabolic Syndrome in the Japanese Population. Metab Syndr Relat Disord 2021;19:225-32. [PMID: 33577395 DOI: 10.1089/met.2020.0121] [Reference Citation Analysis]
493 Cardoso AC, Cravo C, Calçado FL, Rezende G, Campos CFF, Neto JMA, Luz RP, Soares JAS, Moraes-coelho HS, Leite NC, Perez RM, Villela-nogueira CA. The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort. European Journal of Gastroenterology & Hepatology 2020;32:231-8. [DOI: 10.1097/meg.0000000000001496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
494 Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16:391-397. [PMID: 29984130 DOI: 10.1007/s11901-017-0378-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 12.8] [Reference Citation Analysis]
495 Li L, Fu J, Liu D, Sun J, Hou Y, Chen C, Shao J, Wang L, Wang X, Zhao R, Wang H, Andersen ME, Zhang Q, Xu Y, Pi J. Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: Involvement of reduced PPARγ expression. Redox Biol 2020;30:101412. [PMID: 31901728 DOI: 10.1016/j.redox.2019.101412] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
496 Xing B, Zhao Y, Dong B, Zhou Y, Lv W, Zhao W. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. J Diabetes Investig 2020;11:1238-47. [PMID: 32083798 DOI: 10.1111/jdi.13237] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 18.0] [Reference Citation Analysis]
497 Parker R, Weston CJ, Miao Z, Corbett C, Armstrong MJ, Ertl L, Ebsworth K, Walters MJ, Baumart T, Newland D, McMahon J, Zhang P, Singh R, Campbell J, Newsome PN, Charo I, Schall TJ, Adams DH. CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2018;314:G483-93. [PMID: 29420066 DOI: 10.1152/ajpgi.00213.2017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
498 Du Y, Paglicawan L, Soomro S, Abunofal O, Baig S, Vanarsa K, Hicks J, Mohan C. Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization. Nutrients 2021;13:599. [PMID: 33670347 DOI: 10.3390/nu13020599] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
499 Costa G, Cavinato L, Masci C, Fiz F, Sollini M, Politi LS, Chiti A, Balzarini L, Aghemo A, di Tommaso L, Ieva F, Torzilli G, Viganò L. Virtual Biopsy for Diagnosis of Chemotherapy-Associated Liver Injuries and Steatohepatitis: A Combined Radiomic and Clinical Model in Patients with Colorectal Liver Metastases. Cancers (Basel) 2021;13:3077. [PMID: 34203103 DOI: 10.3390/cancers13123077] [Reference Citation Analysis]
500 Xu A, Wang B, Fu J, Qin W, Yu T, Yang Z, Lu Q, Chen J, Chen Y, Wang H. Diet-induced hepatic steatosis activates Ras to promote hepatocarcinogenesis via CPT1α. Cancer Lett 2019;442:40-52. [PMID: 30401637 DOI: 10.1016/j.canlet.2018.10.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
501 Liang Y, Liang S, Zhang Y, Deng Y, He Y, Chen Y, Liu C, Lin C, Yang Q. Oral Administration of Compound Probiotics Ameliorates HFD-Induced Gut Microbe Dysbiosis and Chronic Metabolic Inflammation via the G Protein-Coupled Receptor 43 in Non-alcoholic Fatty Liver Disease Rats. Probiotics Antimicrob Proteins. 2019;11:175-185. [PMID: 29353414 DOI: 10.1007/s12602-017-9378-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 19.0] [Reference Citation Analysis]
502 Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, Chen Y, Li L. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Sci Rep 2016;6:32002. [PMID: 27550547 DOI: 10.1038/srep32002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 22.8] [Reference Citation Analysis]
503 Natarajan Y, Kramer JR, Yu X, Li L, Thrift AP, El-Serag HB, Kanwal F. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology 2020;72:1242-52. [PMID: 32022277 DOI: 10.1002/hep.31157] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
504 Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, Gedulin B, van Vliet AA, Dorenbaum A, Palmer M. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. BMC Gastroenterol 2018;18:3. [PMID: 29304731 DOI: 10.1186/s12876-017-0736-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
505 Leung C, Herath CB, Jia Z, Goodwin M, Mak KY, Watt MJ, Forbes JM, Angus PW. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol. 2014;60:832-838. [PMID: 24316518 DOI: 10.1016/j.jhep.2013.11.033] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
506 Kwak M, Kim D. Long-Term Outcomes of Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2015;14:69-76. [DOI: 10.1007/s11901-015-0258-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
507 Venkatesh SK, Ehman RL. Magnetic resonance elastography of abdomen. Abdom Imaging. 2015;40:745-759. [PMID: 25488346 DOI: 10.1007/s00261-014-0315-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
508 Wang Q, Du H, Li M, Li Y, Liu S, Gao P, Zhang X, Cheng J. MAPK Signal Transduction Pathway Regulation: A Novel Mechanism of Rat HSC-T6 Cell Apoptosis Induced by FUZHENGHUAYU Tablet. Evid Based Complement Alternat Med 2013;2013:368103. [PMID: 23762126 DOI: 10.1155/2013/368103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
509 Chai J, Liu P, Jin E, Su T, Zhang J, Shi K, Hong XU, Yin J, Yu H. MRI chemical shift imaging of the fat content of the pancreas and liver of patients with type 2 diabetes mellitus. Exp Ther Med. 2016;11:476-480. [PMID: 26893633 DOI: 10.3892/etm.2015.2925] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
510 Charlton MR. ChREBP in NASH - a liver transcription factor comes in from the cold. J Hepatol 2013;59:178-9. [PMID: 23523581 DOI: 10.1016/j.jhep.2013.03.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
511 Panahi Y, Kianpour P, Mohtashami R, Soflaei SS, Sahebkar A. Efficacy of phospholipidated curcumin in nonalcoholic fatty liver disease: a clinical study. J Asian Nat Prod Res 2019;21:798-805. [PMID: 30415581 DOI: 10.1080/10286020.2018.1505873] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
512 Zhou CC, Yang X, Hua X, Liu J, Fan MB, Li GQ, Song J, Xu TY, Li ZY, Guan YF, Wang P, Miao CY. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol 2016;173:2352-68. [PMID: 27174364 DOI: 10.1111/bph.13513] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 14.6] [Reference Citation Analysis]
513 Zelber-sagi S, Lotan R, Shibolet O, Webb M, Buch A, Nitzan-kaluski D, Halpern Z, Santo E, Oren R. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int 2013;33:1406-12. [DOI: 10.1111/liv.12200] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
514 Middleton MS, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, Brunt EM, Kleiner DE, Doo E, Van Natta ML, Lavine JE, Neuschwander-Tetri BA, Sanyal A, Loomba R, Sirlin CB; NASH Clinical Research Network. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. Gastroenterology. 2017;153:753-761. [PMID: 28624576 DOI: 10.1053/j.gastro.2017.06.005] [Cited by in Crossref: 120] [Cited by in F6Publishing: 95] [Article Influence: 30.0] [Reference Citation Analysis]
515 Samala N, Tersey SA, Chalasani N, Anderson RM, Mirmira RG. Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase. J Diabetes Complications 2017;31:1630-7. [PMID: 28886991 DOI: 10.1016/j.jdiacomp.2017.07.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
516 Winters-van Eekelen E, Verkouter I, Peters HPF, Alssema M, de Roos BG, Schrauwen-Hinderling VB, Roumans KHM, Schoones JW, Zock PL, Schrauwen P, Rosendaal FR, Dekkers OM, de Mutsert R. Effects of dietary macronutrients on liver fat content in adults: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr 2021;75:588-601. [PMID: 33087892 DOI: 10.1038/s41430-020-00778-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
517 Boga S, Munoz-Abraham AS, Rodriguez-Davalos MI, Emre SH, Jain D, Schilsky ML. Host factors are dominant in the development of post-liver transplant non-alcoholic steatohepatitis. World J Hepatol 2016;8:659-64. [PMID: 27239259 DOI: 10.4254/wjh.v8.i15.659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
518 Dallak MA. Acylated ghrelin induces but deacylated ghrelin prevents hepatic steatosis and insulin resistance in lean rats: Effects on DAG/ PKC/JNK pathway. Biomed Pharmacother 2018;105:299-311. [PMID: 29860222 DOI: 10.1016/j.biopha.2018.05.098] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
519 Runyon BA. A Primer on Detecting Cirrhosis and Caring for These Patients without Causing Harm. Int J Hepatol. 2011;2011:801983. [PMID: 22121492 DOI: 10.4061/2011/801983] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
520 Zhang J, Abbasi O, Malevanchik L, Mohan N, Denicola R, Tarangelo N, Marzio DH. Pilot study of the prevalence of binge eating disorder in non-alcoholic fatty liver disease patients. Ann Gastroenterol 2017;30:664-9. [PMID: 29118561 DOI: 10.20524/aog.2017.0200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
521 DiStefano JK. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. Endocrinology 2020;161:bqaa134. [PMID: 32776116 DOI: 10.1210/endocr/bqaa134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 14.0] [Reference Citation Analysis]
522 Greene MW, Burrington CM, Lynch DT, Davenport SK, Johnson AK, Horsman MJ, Chowdhry S, Zhang J, Sparks JD, Tirrell PC. Lipid metabolism, oxidative stress and cell death are regulated by PKC delta in a dietary model of nonalcoholic steatohepatitis. PLoS One 2014;9:e85848. [PMID: 24454937 DOI: 10.1371/journal.pone.0085848] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
523 Charlton M. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Organ Transplant. 2013;18:251-258. [PMID: 23652610 DOI: 10.1097/mot.0b013e3283615d30] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
524 Turner BJ, Wang C, Melhado TV, Bobadilla R, Jain MK, Singal AG. Significant Increase in Risk of Fibrosis or Cirrhosis at Time of HCV Diagnosis for Hispanics With Diabetes and Obesity Compared With Other Ethnic Groups. Clinical Gastroenterology and Hepatology 2019;17:1356-63. [DOI: 10.1016/j.cgh.2018.11.059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
525 Flessa CM, Kyrou I, Nasiri-Ansari N, Kaltsas G, Papavassiliou AG, Kassi E, Randeva HS. Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives. Curr Obes Rep 2021;10:134-61. [PMID: 33751456 DOI: 10.1007/s13679-021-00431-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
526 Kabbany MN, Conjeevaram Selvakumar PK, Watt K, Lopez R, Akras Z, Zein N, Carey W, Alkhouri N. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol. 2017;112:581-587. [PMID: 28195177 DOI: 10.1038/ajg.2017.5] [Cited by in Crossref: 102] [Cited by in F6Publishing: 79] [Article Influence: 25.5] [Reference Citation Analysis]
527 Jun DW. Practice Guideline for the Diagnosis and Management of Non-alcoholic Fatty Liver Disease. Korean J Gastroenterol 2012;60:64. [DOI: 10.4166/kjg.2012.60.1.64] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
528 Drolz A, Wolter S, Wehmeyer MH, Piecha F, Horvatits T, Schulze Zur Wiesch J, Lohse AW, Mann O, Kluwe J. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. Int J Obes (Lond) 2021. [PMID: 34168277 DOI: 10.1038/s41366-021-00881-8] [Reference Citation Analysis]
529 Yang J, Fernández-Galilea M, Martínez-Fernández L, González-Muniesa P, Pérez-Chávez A, Martínez JA, Moreno-Aliaga MJ. Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. Nutrients 2019;11:E872. [PMID: 31003450 DOI: 10.3390/nu11040872] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 30.0] [Reference Citation Analysis]
530 Yang JD, Abdelmalek MF, Pang H, Guy CD, Smith AD, Diehl AM, Suzuki A. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014;59:1406-1414. [PMID: 24123276 DOI: 10.1002/hep.26761] [Cited by in Crossref: 143] [Cited by in F6Publishing: 120] [Article Influence: 20.4] [Reference Citation Analysis]
531 Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20:205-214. [PMID: 27063264 DOI: 10.1016/j.cld.2015.10.001] [Cited by in Crossref: 247] [Cited by in F6Publishing: 205] [Article Influence: 41.2] [Reference Citation Analysis]
532 Vilar‐gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, Chalasani N. Vitamin E Improves Transplant‐Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. Hepatology 2019;71:495-509. [DOI: 10.1002/hep.30368] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 23.0] [Reference Citation Analysis]
533 Flores YN, Velázquez-Cruz R, Ramírez P, Bañuelos M, Zhang ZF, Yee HF Jr, Chang SC, Canizales-Quinteros S, Quiterio M, Cabrera-Alvarez G, Patiño N, Salmerón J. Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults. Mol Biol Rep 2016;43:1359-69. [PMID: 27752939 DOI: 10.1007/s11033-016-4058-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
534 Samji NS, Verma R, Keri KC, Singal AK, Ahmed A, Rinella M, Bernstein D, Abdelmalek MF, Satapathy SK. Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. Dig Dis Sci 2019;64:3413-30. [PMID: 31312990 DOI: 10.1007/s10620-019-05716-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
535 Ghoneim S, Dhorepatil A, Shah AR, Ram G, Ahmad S, Kim C, Asaad I. Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study. World J Hepatol 2020;12:378-88. [PMID: 32821336 DOI: 10.4254/wjh.v12.i7.378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
536 Fuchs CD, Claudel T, Kumari P, Haemmerle G, Pollheimer MJ, Stojakovic T, Scharnagl H, Halilbasic E, Gumhold J, Silbert D. Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice. Hepatology. 2012;56:270-280. [PMID: 22271167 DOI: 10.1002/hep.25601] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
537 Muscogiuri G, Cantone E, Cassarano S, Tuccinardi D, Barrea L, Savastano S, Colao A; on behalf of the Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Gut microbiota: a new path to treat obesity. Int J Obes Suppl 2019;9:10-9. [PMID: 31391921 DOI: 10.1038/s41367-019-0011-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 54] [Article Influence: 36.0] [Reference Citation Analysis]
538 Seko Y, Sumida Y, Sasaki K, Itoh Y, Iijima H, Hashimoto T, Ishii S, Inagaki N. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol 2018;53:140-51. [DOI: 10.1007/s00535-017-1364-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
539 Cordoba-Chacon J. Loss of Hepatocyte-Specific PPARγ Expression Ameliorates Early Events of Steatohepatitis in Mice Fed the Methionine and Choline-Deficient Diet. PPAR Res 2020;2020:9735083. [PMID: 32411189 DOI: 10.1155/2020/9735083] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
540 Liu M, Li L, Chu J, Zhu B, Zhang Q, Yin X, Jiang W, Dai G, Ju W, Wang Z. Serum N1-methylnicotinamide is associated with obesity and diabetes in Chinese. J Clin Endocrinol Metab. 2015;100:3112-3117. [PMID: 26066674 DOI: 10.1210/jc.2015-1732] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 7.7] [Reference Citation Analysis]
541 Sima A, Timar R, Vlad A, Timar B, Rosu M, Dan I, Sirli R, Popescu A, Sporea I. Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients. Wien Klin Wochenschr 2014;126:335-40. [PMID: 24652019 DOI: 10.1007/s00508-014-0530-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
542 Jia X, Iwanowycz S, Wang J, Saaoud F, Yu F, Wang Y, Hu J, Chatterjee S, Wang Q, Fan D. Emodin attenuates systemic and liver inflammation in hyperlipidemic mice administrated with lipopolysaccharides. Exp Biol Med (Maywood) 2014;239:1025-35. [PMID: 24740873 DOI: 10.1177/1535370214530247] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
543 Pickett-Blakely O, Young K, Carr RM. Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis. Cell Mol Gastroenterol Hepatol. 2018;6:451-462. [PMID: 30294653 DOI: 10.1016/j.jcmgh.2018.07.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
544 Salarian M, Turaga RC, Xue S, Nezafati M, Hekmatyar K, Qiao J, Zhang Y, Tan S, Ibhagui OY, Hai Y, Li J, Mukkavilli R, Sharma M, Mittal P, Min X, Keilholz S, Yu L, Qin G, Farris AB, Liu ZR, Yang JJ. Early detection and staging of chronic liver diseases with a protein MRI contrast agent. Nat Commun 2019;10:4777. [PMID: 31664017 DOI: 10.1038/s41467-019-11984-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
545 Di Ciaula A, Calamita G, Shanmugam H, Khalil M, Bonfrate L, Wang DQ, Baffy G, Portincasa P. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. Int J Mol Sci 2021;22:7702. [PMID: 34299321 DOI: 10.3390/ijms22147702] [Reference Citation Analysis]
546 Soti S, Corey KE, Lake JE, Erlandson KM. NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk? Curr HIV/AIDS Rep 2018;15:212-22. [PMID: 29671204 DOI: 10.1007/s11904-018-0392-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
547 Lee YH, Kim JH, Kim SR, Jin HY, Rhee EJ, Cho YM, Lee BW. Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness. J Korean Med Sci 2017;32:60-9. [PMID: 27914133 DOI: 10.3346/jkms.2017.32.1.60] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
548 Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015;25:3282-3294. [PMID: 25994191 DOI: 10.1007/s00330-015-3731-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
549 Camporez JP, Jornayvaz FR, Petersen MC, Pesta D, Guigni BA, Serr J, Zhang D, Kahn M, Samuel VT, Jurczak MJ. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology. 2013;154:3099-3109. [PMID: 23766126 DOI: 10.1210/en.2013-1191] [Cited by in Crossref: 125] [Cited by in F6Publishing: 114] [Article Influence: 15.6] [Reference Citation Analysis]
550 Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:637-653. [PMID: 25194181 DOI: 10.1016/j.bpg.2014.07.008] [Cited by in Crossref: 189] [Cited by in F6Publishing: 147] [Article Influence: 27.0] [Reference Citation Analysis]
551 Carlsson B, Lindén D, Brolén G, Liljeblad M, Bjursell M, Romeo S, Loomba R. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2020;51:1305-20. [PMID: 32383295 DOI: 10.1111/apt.15738] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
552 Cruz JF, Cruz MA, Machado Neto J, de Santana DS, Oliveira CC, Lima SO. Prevalence and sonographic changes compatible with fatty liver disease in patients referred for abdominal ultrasound examination in Aracaju, SE. Radiol Bras. 2016;49:1-5. [PMID: 26929453 DOI: 10.1590/0100-3984.2014.0124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
553 Linares I, Hamar M, Selzner N, Selzner M. Steatosis in Liver Transplantation: Current Limitations and Future Strategies. Transplantation 2019;103:78-90. [DOI: 10.1097/tp.0000000000002466] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 15.5] [Reference Citation Analysis]
554 Conti F, Vukotic R, Foschi FG, Domenicali M, Giacomoni P, Savini S, Lanzi A, Dall’aglio AC, Saini G, Matroroberto M, Bernardi M, Stefanini GF, Andreone P. Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholic fatty liver disease: An Italian community-based population study. Digestive and Liver Disease 2016;48:1357-63. [DOI: 10.1016/j.dld.2016.07.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
555 Vongsuvanh R, van der Poorten D, Iseli T, Strasser SI, McCaughan GW, George J. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PLoS One. 2016;11:e0155800. [PMID: 27219517 DOI: 10.1371/journal.pone.0155800] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
556 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839] [Reference Citation Analysis]
557 Vreman RA, Goodell AJ, Rodriguez LA, Porco TC, Lustig RH, Kahn JG. Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model. BMJ Open 2017;7:e013543. [PMID: 28775179 DOI: 10.1136/bmjopen-2016-013543] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 6.8] [Reference Citation Analysis]
558 Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19:8301-8311. [PMID: 24363521 DOI: 10.3748/wjg.v19.i45.8301] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
559 Udompap P, Kim D, Kim WR. Current and Future Burden of Chronic Nonmalignant Liver Disease. Clin Gastroenterol Hepatol. 2015;13:2031-2041. [PMID: 26291665 DOI: 10.1016/j.cgh.2015.08.015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 11.5] [Reference Citation Analysis]
560 Xie Y, Zhang H, Jin C, Wang X, Wang X, Chen J, Xu Y. Gd-EOB-DTPA-enhanced T1ρ imaging vs diffusion metrics for assessment liver inflammation and early stage fibrosis of nonalcoholic steatohepatitis in rabbits. Magnetic Resonance Imaging 2018;48:34-41. [DOI: 10.1016/j.mri.2017.12.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
561 Wang X, Xie J, Pang J, Zhang H, Chen X, Lin J, Li Q, Chen Q, Ma J, Xu X, Yang Y, Ling W, Chen Y. Serum SHBG Is Associated With the Development and Regression of Nonalcoholic Fatty Liver Disease: A Prospective Study. J Clin Endocrinol Metab 2020;105:dgz244. [PMID: 31793624 DOI: 10.1210/clinem/dgz244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
562 Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther. 2015;41:368-378. [PMID: 25496369 DOI: 10.1111/apt.13052] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
563 Jasirwan COM, Muradi A, Hasan I, Simadibrata M, Rinaldi I. Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. Biosci Microbiota Food Health 2021;40:50-8. [PMID: 33520569 DOI: 10.12938/bmfh.2020-046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
564 van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The Effects of Physical Exercise on Fatty Liver Disease. Gene Expr 2018;18:89-101. [PMID: 29212576 DOI: 10.3727/105221617X15124844266408] [Cited by in Crossref: 79] [Cited by in F6Publishing: 38] [Article Influence: 19.8] [Reference Citation Analysis]
565 Schneider AL, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity (Silver Spring). 2014;22:292-299. [PMID: 23512725 DOI: 10.1002/oby.20426] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 9.0] [Reference Citation Analysis]
566 Parente DB, Rodrigues RS, Paiva FF, Oliveira Neto JA, Machado-Silva L, Lanzoni V, Campos CF, Eiras-Araujo AL, do Brasil PE, Garteiser P, Gomes MB, de Mello Perez R. Is MR spectroscopy really the best MR-based method for the evaluation of fatty liver in diabetic patients in clinical practice? PLoS One 2014;9:e112574. [PMID: 25426708 DOI: 10.1371/journal.pone.0112574] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
567 Giblin RJ, Bennett EJ, Zosky GR, Dwyer RM. The Impact of Sex and 25(OH)D Deficiency on Metabolic Function in Mice. Nutrients 2017;9:E985. [PMID: 28880231 DOI: 10.3390/nu9090985] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
568 Vineeth Daniel P, Kamthan M, Gera R, Dogra S, Gautam K, Ghosh D, Mondal P. Chronic exposure to Pb2+ perturbs ChREBP transactivation and coerces hepatic dyslipidemia. FEBS Lett 2019;593:3084-97. [PMID: 31309533 DOI: 10.1002/1873-3468.13538] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
569 Wollenman CS, Chason R, Reisch JS, Rockey DC. Impact of ethnicity in upper gastrointestinal hemorrhage. J Clin Gastroenterol 2014;48:343-50. [PMID: 24275716 DOI: 10.1097/MCG.0000000000000025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
570 Lazaridis N, Tsochatzis E. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Review of Gastroenterology & Hepatology 2017;11:357-69. [DOI: 10.1080/17474124.2017.1293523] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
571 Leopold C, Duta-Mare M, Sachdev V, Goeritzer M, Maresch LK, Kolb D, Reicher H, Wagner B, Stojakovic T, Ruelicke T, Haemmerle G, Hoefler G, Sattler W, Kratky D. Hepatocyte-specific lysosomal acid lipase deficiency protects mice from diet-induced obesity but promotes hepatic inflammation. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:500-511. [PMID: 30639734 DOI: 10.1016/j.bbalip.2019.01.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
572 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
573 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 9.4] [Reference Citation Analysis]
574 Li D, Long W, Huang R, Chen Y, Xia M. 27‐Hydroxycholesterol Inhibits Sterol Regulatory Element‐Binding Protein 1 Activation and Hepatic Lipid Accumulation in Mice. Obesity 2018;26:713-22. [DOI: 10.1002/oby.22130] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
575 Kumar R, Porwal YC, Dev N, Kumar P, Chakravarthy S, Kumawat A. Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian Indians: A cross-sectional study. J Family Med Prim Care 2020;9:390-4. [PMID: 32110624 DOI: 10.4103/jfmpc.jfmpc_887_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
576 Lazo M, Rubin J, Clark JM, Coresh J, Schneider AL, Ndumele C, Hoogeveen RC, Ballantyne CM, Selvin E. The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. J Hepatol. 2015;62:841-847. [PMID: 25433159 DOI: 10.1016/j.jhep.2014.11.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
577 Giard JM, Terrault NA. Women with Cirrhosis: Prevalence, Natural History, and Management. Gastroenterol Clin North Am. 2016;45:345-358. [PMID: 27261903 DOI: 10.1016/j.gtc.2016.02.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
578 Martin-Rodriguez JL, Gonzalez-Cantero J, Gonzalez-Cantero A, Arrebola JP, Gonzalez-Calvin JL. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. Medicine (Baltimore). 2017;96:e6770. [PMID: 28445310 DOI: 10.1097/md.0000000000006770] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
579 Chung HK, Nam JS, Lee MY, Kim YB, Won YS, Song WJ, Kim YH, Ahn CW, Sung KC. The increased amount of coffee consumption lowers the incidence of fatty liver disease in Korean men. Nutr Metab Cardiovasc Dis 2020;30:1653-61. [PMID: 32631703 DOI: 10.1016/j.numecd.2020.05.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
580 Weiß J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int 2014;111:447-52. [PMID: 25019921 DOI: 10.3238/arztebl.2014.0447] [Cited by in Crossref: 19] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
581 Anty R, Lemoine M. Liver fibrogenesis and metabolic factors. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1:S10-S20. [PMID: 21742296 DOI: 10.1016/s2210-7401(11)70003-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
582 Tada T, Toyoda H, Sone Y, Yasuda S, Miyake N, Kumada T, Tanaka J. Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle‐aged patients with non‐alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2019;34:2011-8. [DOI: 10.1111/jgh.14734] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
583 Aguirre L, Portillo MP, Hijona E, Bujanda L. Effects of resveratrol and other polyphenols in hepatic steatosis. World J Gastroenterol. 2014;20:7366-7380. [PMID: 24966607 DOI: 10.3748/wjg.v20.i23.7366] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 72] [Article Influence: 14.2] [Reference Citation Analysis]
584 Hu X, Huang Y, Bao Z, Wang Y, Shi D, Liu F, Gao Z, Yu X. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterol. 2012;12:123. [PMID: 22978800 DOI: 10.1186/1471-230x-12-123] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
585 Reddy SK, Reilly C, Zhan M, Mindikoglu AL, Jiang Y, Lane BF, Alexander HR, Culpepper WJ, El-Kamary SS. Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis. Med Oncol 2014;31:971. [PMID: 24798875 DOI: 10.1007/s12032-014-0971-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
586 McCullough A, Previs S, Kasumov T. Stable isotope-based flux studies in nonalcoholic fatty liver disease. Pharmacol Ther 2018;181:22-33. [PMID: 28720429 DOI: 10.1016/j.pharmthera.2017.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
587 Zhang X, Fan L, Wu J, Xu H, Leung WY, Fu K, Wu J, Liu K, Man K, Yang X, Han J, Ren J, Yu J. Macrophage p38α promotes nutritional steatohepatitis through M1 polarization. J Hepatol 2019;71:163-74. [PMID: 30914267 DOI: 10.1016/j.jhep.2019.03.014] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
588 Loy VM, Joyce C, Bello S, Vonroenn N, Cotler SJ. Gender disparities in liver transplant candidates with nonalcoholic steatohepatitis. Clin Transplant 2018;32:e13297. [DOI: 10.1111/ctr.13297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
589 Aby E, Phan J, Truong E, Grotts J, Saab S. Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis. Journal of Clinical Gastroenterology 2019;53:142-6. [DOI: 10.1097/mcg.0000000000001075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
590 Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: Current and emerging. Journal of Hepatology 2018;68:362-75. [DOI: 10.1016/j.jhep.2017.10.015] [Cited by in Crossref: 139] [Cited by in F6Publishing: 117] [Article Influence: 46.3] [Reference Citation Analysis]
591 Puppala J, Bhrugumalla S, Kumar A, Siddapuram SP, Viswa PD, Kondawar M, Akka J, Munshi A. Apolipoprotein C3 gene polymorphisms in Southern Indian patients with nonalcoholic fatty liver disease. Indian J Gastroenterol. 2014;33:524-529. [PMID: 25319715 DOI: 10.1007/s12664-014-0504-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
592 Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X, Asch SM, El‐serag HB. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology 2020;71:808-19. [DOI: 10.1002/hep.31014] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 42.0] [Reference Citation Analysis]
593 Muzica CM, Sfarti C, Trifan A, Zenovia S, Cuciureanu T, Nastasa R, Huiban L, Cojocariu C, Singeap AM, Girleanu I, Chiriac S, Stanciu C. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship. Can J Gastroenterol Hepatol 2020;2020:6638306. [PMID: 33425804 DOI: 10.1155/2020/6638306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
594 Kroy DC, Schumacher F, Ramadori P, Hatting M, Bergheim I, Gassler N, Boekschoten MV, Müller M, Streetz KL, Trautwein C. Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice. J Hepatol 2014;61:883-90. [PMID: 24845607 DOI: 10.1016/j.jhep.2014.05.019] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
595 Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in Nonalcoholic Steatohepatitis. Elsevier; 2013. pp. 67-125. [DOI: 10.1016/b978-0-12-407680-8.00004-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
596 Zhang SR, Fan XM. Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2015;21:3214-3222. [PMID: 25805927 DOI: 10.3748/wjg.v21.i11.3214] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
597 Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity. Gastroenterology. 2017;152:1656-1670. [PMID: 28192107 DOI: 10.1053/j.gastro.2016.12.052] [Cited by in Crossref: 81] [Cited by in F6Publishing: 44] [Article Influence: 20.3] [Reference Citation Analysis]
598 Thandra KC, Barsouk A, Saginala K, Aluru JS, Rawla P, Barsouk A. Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression. Clin Exp Hepatol 2020;6:289-94. [PMID: 33511275 DOI: 10.5114/ceh.2020.102153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
599 Paschou SA, Polyzos SA, Anagnostis P, Goulis DG, Kanaka-Gantenbein C, Lambrinoudaki I, Georgopoulos NA, Vryonidou A. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine 2020;67:1-8. [PMID: 31538291 DOI: 10.1007/s12020-019-02085-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
600 Abdelmegeed MA, Ha SK, Choi Y, Akbar M, Song BJ. Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances. Curr Mol Pharmacol 2017;10:207-25. [PMID: 26278393 DOI: 10.2174/1874467208666150817111114] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 17.5] [Reference Citation Analysis]
601 Lu Z, Li Y, Syn WK, Li AJ, Ritter S, Wank SA, Lopes-Virella MF, Huang Y. GPR40-Deficiency Is Associated with Hepatic FAT/CD36 Upregulation, Steatosis, Inflammation and Cell Injury in C57BL/6 Mice. Am J Physiol Endocrinol Metab. 2020;. [PMID: 33103454 DOI: 10.1152/ajpendo.00257.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
602 Benmassaoud A, Ghali P, Cox J, Wong P, Szabo J, Deschenes M, Osikowicz M, Lebouche B, Klein MB, Sebastiani G. Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. PLoS One. 2018;13:e0191985. [PMID: 29381754 DOI: 10.1371/journal.pone.0191985] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
603 Ping F, Li ZY, Lv K, Zhou MC, Dong YX, Sun Q, Li YX. Deoxyribonucleic acid telomere length shortening can predict the incidence of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Diabetes Investig 2017;8:174-80. [PMID: 27451965 DOI: 10.1111/jdi.12555] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
604 Bruno Ade S, Rodrigues MH, Alvares MC, Nahas-Neto J, Nahas EA. Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women. Climacteric. 2014;17:465-471. [PMID: 24517420 DOI: 10.3109/13697137.2014.881353] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
605 Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, Behling C, Loomba R; NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58:1644-1654. [PMID: 23686698 DOI: 10.1002/hep.26465] [Cited by in Crossref: 103] [Cited by in F6Publishing: 88] [Article Influence: 12.9] [Reference Citation Analysis]
606 Su X, Xu J, Zheng C. The relationship between non-alcoholic fatty liver and skeletal muscle mass to visceral fat area ratio in women with type 2 diabetes. BMC Endocr Disord 2019;19:76. [PMID: 31315613 DOI: 10.1186/s12902-019-0404-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
607 Ghaemi A, Taleban FA, Hekmatdoost A, Rafiei A, Hosseini V, Amiri Z, Homayounfar R, Fakheri H. How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease? Hepat Mon. 2013;13:e15227. [PMID: 24358045 DOI: 10.5812/hepatmon.15227] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
608 Moylan CA, Pang H, Dellinger A, Suzuki A, Garrett ME, Guy CD, Murphy SK, Ashley-Koch AE, Choi SS, Michelotti GA, Hampton DD, Chen Y, Tillmann HL, Hauser MA, Abdelmalek MF, Diehl AM. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 2014;59:471-82. [PMID: 23913408 DOI: 10.1002/hep.26661] [Cited by in Crossref: 170] [Cited by in F6Publishing: 155] [Article Influence: 21.3] [Reference Citation Analysis]
609 Li R, Liao XH, Ye JZ, Li MR, Wu YQ, Hu X, Zhong BH. Association of keratin 8/18 variants with non-alcoholic fatty liver disease and insulin resistance in Chinese patients: A case-control study. World J Gastroenterol 2017;23:4047-53. [PMID: 28652657 DOI: 10.3748/wjg.v23.i22.4047] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
610 Zeb I, Katz R, Nasir K, Ding J, Rezaeian P, Budoff MJ. Relation of nonalcoholic fatty liver disease to the metabolic syndrome: the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Comput Tomogr 2013;7:311-8. [PMID: 24268118 DOI: 10.1016/j.jcct.2013.08.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
611 Jeong JY, Sohn JH, Baek YH, Cho YK, Kim Y, Kim H. New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial. World J Gastroenterol 2017;23:5977-85. [PMID: 28932090 DOI: 10.3748/wjg.v23.i32.5977] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
612 Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73:1-14. [PMID: 23329465 DOI: 10.1007/s40265-012-0004-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 13.1] [Reference Citation Analysis]
613 Musolino V, Gliozzi M, Bombardelli E, Nucera S, Carresi C, Maiuolo J, Mollace R, Paone S, Bosco F, Scarano F, Scicchitano M, Macrì R, Ruga S, Zito MC, Palma E, Gratteri S, Ragusa M, Volterrani M, Fini M, Mollace V. The synergistic effect of Citrus bergamia and Cynara cardunculus extracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease. J Tradit Complement Med 2020;10:268-74. [PMID: 32670822 DOI: 10.1016/j.jtcme.2020.02.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
614 Roychowdhury S, Selvakumar PC, Cresci GAM. The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. Med Sci (Basel) 2018;6:E47. [PMID: 29874807 DOI: 10.3390/medsci6020047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
615 Cervo A, Shengir M, Patel K, Sebastiani G. NASH in HIV. Curr HIV/AIDS Rep 2020;17:601-14. [PMID: 32984925 DOI: 10.1007/s11904-020-00531-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
616 Wong SW, Ting YW, Chan WK. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications. JGH Open 2018;2:235-41. [PMID: 30483595 DOI: 10.1002/jgh3.12070] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
617 Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl 2016;22:178-87. [PMID: 26479422 DOI: 10.1002/lt.24360] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
618 Flores YN, Zhang ZF, Bastani R, Leng M, Crespi CM, Ramírez-Palacios P, Stevens H, Salmerón J. Risk factors for liver disease among adults of Mexican descent in the United States and Mexico. World J Gastroenterol 2018;24:4281-90. [PMID: 30310261 DOI: 10.3748/wjg.v24.i37.4281] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
619 Yang C, Hallmark B, Chai JC, O'Connor TD, Reynolds LM, Wood AC, Seeds M, Chen YI, Steffen LM, Tsai MY, Kaplan RC, Daviglus ML, Mandarino LJ, Fretts AM, Lemaitre RN, Coletta DK, Blomquist SA, Johnstone LM, Tontsch C, Qi Q, Ruczinski I, Rich SS, Mathias RA, Chilton FH, Manichaikul A. Impact of Amerind ancestry and FADS genetic variation on omega-3 deficiency and cardiometabolic traits in Hispanic populations. Commun Biol 2021;4:918. [PMID: 34321601 DOI: 10.1038/s42003-021-02431-4] [Reference Citation Analysis]
620 Harrison SA, Gawrieh S, Roberts K, Lisanti CJ, Schwope RB, Cebe KM, Paradis V, Bedossa P, Aldridge Whitehead JM, Labourdette A, Miette V, Neubauer S, Fournier C, Paredes AH, Alkhouri N. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol 2021;75:284-91. [PMID: 33746083 DOI: 10.1016/j.jhep.2021.02.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
621 Peng K, Mo Z, Tian G. Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males. Am J Med Sci 2017;353:236-41. [PMID: 28262209 DOI: 10.1016/j.amjms.2017.01.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
622 Stevanović J, Beleza J, Coxito P, Ascensão A, Magalhães J. Physical exercise and liver "fitness": Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease. Mol Metab 2020;32:1-14. [PMID: 32029220 DOI: 10.1016/j.molmet.2019.11.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
623 Zhang XQ, Xu CF, Yu CH, Chen WX, Li YM. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:1768-1776. [PMID: 24587654 DOI: 10.3748/wjg.v20.i7.1768] [Cited by in CrossRef: 138] [Cited by in F6Publishing: 121] [Article Influence: 23.0] [Reference Citation Analysis]
624 Parisinos CA, Wilman HR, Thomas EL, Kelly M, Nicholls RC, McGonigle J, Neubauer S, Hingorani AD, Patel RS, Hemingway H, Bell JD, Banerjee R, Yaghootkar H. Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. J Hepatol 2020;73:241-51. [PMID: 32247823 DOI: 10.1016/j.jhep.2020.03.032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 20.0] [Reference Citation Analysis]
625 Ballester-Vallés C, Flores-Méndez J, Delgado-Moraleda J, Ballesteros Martín-Portugués A, Merino-Torres JF, Fornés-Ferrer V, Martí-Bonmatí L. Hepatic and pancreatic fat as imaging biomarkers of metabolic syndrome. Radiologia (Engl Ed) 2020;62:122-30. [PMID: 31447050 DOI: 10.1016/j.rx.2019.05.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
626 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
627 Tsuchiya S, Amano Y, Isono O, Imai M, Shimizu F, Asada M, Imai S, Harada A, Yasuhara Y, Tozawa R, Nagabukuro H. Pharmacological evaluation of pioglitazone and candesartan cilexetil in a novel mouse model of non-alcoholic steatohepatitis, modified choline-deficient, amino acid-defined diet fed low-density lipoprotein receptor knockout mice: Pharmacological validation of mouse model of NASH. Hepatol Res 2017;47:584-92. [DOI: 10.1111/hepr.12773] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
628 Castaño-Rodríguez N, Mitchell HM, Kaakoush NO. NAFLD, Helicobacter species and the intestinal microbiome. Best Pract Res Clin Gastroenterol 2017;31:657-68. [PMID: 29566909 DOI: 10.1016/j.bpg.2017.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
629 Yang YJ, Bang CS, Shin SP, Baik GH. Clinical impact of non-alcoholic fatty liver disease on the occurrence of colorectal neoplasm: Propensity score matching analysis. PLoS One 2017;12:e0182014. [PMID: 28777831 DOI: 10.1371/journal.pone.0182014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
630 Boucher MP, Lefebvre C, Chapados NA. The effects of PCB126 on intra-hepatic mechanisms associated with non alcoholic fatty liver disease. J Diabetes Metab Disord 2015;14:88. [PMID: 26693162 DOI: 10.1186/s40200-015-0218-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
631 Rahman K, Desai C, Iyer SS, Thorn NE, Kumar P, Liu Y, Smith T, Neish AS, Li H, Tan S, Wu P, Liu X, Yu Y, Farris AB, Nusrat A, Parkos CA, Anania FA. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. Gastroenterology. 2016;151:733-746.e12. [PMID: 27342212 DOI: 10.1053/j.gastro.2016.06.022] [Cited by in Crossref: 127] [Cited by in F6Publishing: 110] [Article Influence: 25.4] [Reference Citation Analysis]
632 Askari F, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res. 2014;34:143-148. [PMID: 24461315 DOI: 10.1016/j.nutres.2013.11.005] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 9.3] [Reference Citation Analysis]
633 Toshikuni N, Tsutsumi M, Arisawa T. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:8393-406. [PMID: 25024597 DOI: 10.3748/wjg.v20.i26.8393] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
634 Wáng YXJ. Gender-specific liver aging and magnetic resonance imaging. Quant Imaging Med Surg 2021;11:2893-904. [PMID: 34249621 DOI: 10.21037/qims-21-227] [Reference Citation Analysis]
635 Chiang H, Lu HF, Chen JC, Chen YH, Sun HT, Huang HC, Tien HH, Huang C. Adlay Seed (Coix lacryma-jobi L.) Extracts Exhibit a Prophylactic Effect on Diet-Induced Metabolic Dysfunction and Nonalcoholic Fatty Liver Disease in Mice. Evid Based Complement Alternat Med 2020;2020:9519625. [PMID: 32595752 DOI: 10.1155/2020/9519625] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
636 Zhao J, Jiao Y, Song Y, Liu J, Li X, Zhang H, Yang J, Lu Y. Stanniocalcin 2 Ameliorates Hepatosteatosis Through Activation of STAT3 Signaling. Front Physiol 2018;9:873. [PMID: 30038584 DOI: 10.3389/fphys.2018.00873] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
637 Quintana-Castro R, Aguirre-Maldonado I, Soto-Rodríguez I, Deschamps-Lago RA, Gruber-Pagola P, Urbina de Larrea YK, Juárez-Rivera VE, Ramos-Manuel LE, Alexander-Aguilera A. Cd36 gene expression in adipose and hepatic tissue mediates the lipids accumulation in liver of obese rats with sucrose-induced hepatic steatosis. Prostaglandins Other Lipid Mediat 2020;147:106404. [PMID: 31838198 DOI: 10.1016/j.prostaglandins.2019.106404] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
638 Zhao F, Zhou N, Wang JL, Zhou H, Zou LQ, Zhong WX, He J, Zheng CJ, Yan SX, Wáng YXJ. Collagen deposition in the liver is strongly and positively associated with T1rho elongation while fat deposition is associated with T1rho shortening: an experimental study of methionine and choline-deficient (MCD) diet rat model. Quant Imaging Med Surg 2020;10:2307-21. [PMID: 33269229 DOI: 10.21037/qims-20-651] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
639 Motamed N, Faraji AH, Khonsari MR, Maadi M, Tameshkel FS, Keyvani H, Ajdarkosh H, Karbalaie Niya MH, Rezaie N, Zamani F. Fatty liver index (FLI) and prediction of new cases of non-alcoholic fatty liver disease: A population-based study of northern Iran. Clin Nutr 2020;39:468-74. [PMID: 30922791 DOI: 10.1016/j.clnu.2019.02.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
640 Josef P, Ali I, Ariel P, Alon M, Nimer A. Relationship between retinal vascular caliber and coronary artery disease in patients with non-alcoholic fatty liver disease (NAFLD). Int J Environ Res Public Health. 2013;10:3409-3423. [PMID: 23924883 DOI: 10.3390/ijerph10083409] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
641 Li D, Xie P, Zhao S, Zhao J, Yao Y, Zhao Y, Ren G, Liu X. Hepatocytes derived increased SAA1 promotes intrahepatic platelet aggregation and aggravates liver inflammation in NAFLD. Biochem Biophys Res Commun 2021;555:54-60. [PMID: 33813276 DOI: 10.1016/j.bbrc.2021.02.124] [Reference Citation Analysis]
642 Shimizu M, Tanaka T, Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol. 2013;35:191-202. [PMID: 22945457 DOI: 10.1007/s00281-012-0336-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
643 Awad AS, Abd Al Haleem EN, El-Bakly WM, Sherief MA. Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis. Naunyn Schmiedebergs Arch Pharmacol 2016;389:381-91. [PMID: 26753695 DOI: 10.1007/s00210-015-1207-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 6.6] [Reference Citation Analysis]
644 Nyakudya TT, Mukwevho E, Nkomozepi P, Erlwanger KH. Neonatal intake of oleanolic acid attenuates the subsequent development of high fructose diet-induced non-alcoholic fatty liver disease in rats. J Dev Orig Health Dis. 2018;9:500-510. [PMID: 29792584 DOI: 10.1017/s2040174418000259] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
645 Lemoine M, Serfaty L. [Nonalcoholic fatty liver disease]. Presse Med 2012;41:169-89. [PMID: 21723084 DOI: 10.1016/j.lpm.2011.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
646 Chen L, Huang P, Chien C, Lin C, Chien R. A community-based study on the application of fatty liver index in screening subjects with nonalcoholic fatty liver disease. Journal of the Formosan Medical Association 2020;119:173-81. [DOI: 10.1016/j.jfma.2019.03.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
647 Li L, Fu J, Sun J, Liu D, Chen C, Wang H, Hou Y, Xu Y, Pi J. Is Nrf2-ARE a potential target in NAFLD mitigation? Current Opinion in Toxicology 2019;13:35-44. [DOI: 10.1016/j.cotox.2018.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
648 Vuppalanchi R, Sanyal AJ. Myths and mysteries about staging hepatic fibrosis by fibroscan. Clin Gastroenterol Hepatol 2015;13:780-2. [PMID: 25451885 DOI: 10.1016/j.cgh.2014.10.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
649 Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol 2014;20:9330-7. [PMID: 25071327 DOI: 10.3748/wjg.v20.i28.9330] [Cited by in F6Publishing: 105] [Reference Citation Analysis]
650 Bahitham W, Watts R, Nelson R, Lian J, Lehner R. Liver-specific expression of carboxylesterase 1g/esterase-x reduces hepatic steatosis, counteracts dyslipidemia and improves insulin signaling. Biochim Biophys Acta 2016;1861:482-90. [PMID: 26976727 DOI: 10.1016/j.bbalip.2016.03.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
651 Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B, Seki E, Sirlin CB, Loomba R. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015;13:561-568.e1. [PMID: 25218667 DOI: 10.1016/j.cgh.2014] [Reference Citation Analysis]
652 Hamar M, Selzner M. Steatotic donor livers: Where is the risk-benefit maximized?: Hamar and Selzner. Liver Transpl 2017;23:S34-9. [DOI: 10.1002/lt.24826] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
653 Wahlang B, Song M, Beier JI, Cameron Falkner K, Al-Eryani L, Clair HB, Prough RA, Osborne TS, Malarkey DE, States JC, Cave MC. Evaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver disease. Toxicol Appl Pharmacol 2014;279:380-90. [PMID: 24998970 DOI: 10.1016/j.taap.2014.06.019] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 8.7] [Reference Citation Analysis]
654 Reichman TW, Therapondos G, Serrano MS, Seal J, Evers-Meltzer R, Bohorquez H, Cohen A, Carmody I, Ahmed E, Bruce D, Loss GE. "Weighing the risk": Obesity and outcomes following liver transplantation. World J Hepatol 2015;7:1484-93. [PMID: 26085908 DOI: 10.4254/wjh.v7.i11.1484] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
655 Harman DJ, Ryder SD, James MW, Jelpke M, Ottey DS, Wilkes EA, Card TR, Aithal GP, Guha IN. Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. BMJ Open 2015;5:e007516. [PMID: 25941185 DOI: 10.1136/bmjopen-2014-007516] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
656 Virarkar M, Szklaruk J, Jensen CT, Taggart MW, Bhosale P. What's New in Hepatic Steatosis. Semin Ultrasound CT MR 2021;42:405-15. [PMID: 34130852 DOI: 10.1053/j.sult.2021.03.001] [Reference Citation Analysis]
657 Pagadala MR, McCullough AJ. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis. 2012;16:487-504. [PMID: 22824477 DOI: 10.1016/j.cld.2012.05.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
658 Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48:97-113. [PMID: 21875310 DOI: 10.3109/10408363.2011.596521] [Cited by in Crossref: 183] [Cited by in F6Publishing: 160] [Article Influence: 18.3] [Reference Citation Analysis]
659 Rahman K, Liu Y, Kumar P, Smith T, Thorn NE, Farris AB, Anania FA. C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis. Lab Invest 2016;96:895-908. [PMID: 27239734 DOI: 10.1038/labinvest.2016.61] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
660 Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37 Suppl 1:97-103. [PMID: 28052626 DOI: 10.1111/liv.13302] [Cited by in Crossref: 107] [Cited by in F6Publishing: 93] [Article Influence: 26.8] [Reference Citation Analysis]
661 Kanwal F, Kramer JR, Duan Z, Yu X, White D, El-Serag HB. Trends in the Burden of Non-alcoholic Fatty Liver Disease in a US Cohort of Veterans. Clin Gastroenterol Hepatol. 2015; Aug 17. [Epub ahead of print]. [PMID: 26291667 DOI: 10.4103/1119-3077] [Reference Citation Analysis]
662 Linge J, Ekstedt M, Dahlqvist Leinhard O. Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. JHEP Rep 2021;3:100197. [PMID: 33598647 DOI: 10.1016/j.jhepr.2020.100197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
663 Noureddin M, Rinella ME. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis 2015;19:361-79. [PMID: 25921668 DOI: 10.1016/j.cld.2015.01.012] [Cited by in Crossref: 94] [Cited by in F6Publishing: 76] [Article Influence: 15.7] [Reference Citation Analysis]
664 Kanwal F, Kramer JR, Duan Z, Yu X, White D, El-Serag HB. Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. Clin Gastroenterol Hepatol. 2016;14:301-308.e1-2. [PMID: 26291667 DOI: 10.1016/j.cgh.2015.08.010] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 13.8] [Reference Citation Analysis]
665 Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020;323:1175-1183. [PMID: 32207804 DOI: 10.1001/jama.2020.2298] [Cited by in Crossref: 119] [Cited by in F6Publishing: 96] [Article Influence: 119.0] [Reference Citation Analysis]
666 Townsend SA, Newsome PN. Review article: new treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:494-507. [PMID: 28677333 DOI: 10.1111/apt.14210] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
667 Wang X, Ji D, Zhu B, Jiang S, Han L, Wang Y, Mai H, Xu S, Jiang H, Wang G, Rong Y. Contribution of endotoxin to Th17 bias in patients with non-alcoholic steatohepatitis. Microb Pathog 2020;142:104009. [PMID: 32001302 DOI: 10.1016/j.micpath.2020.104009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
668 Xie LT, Yan CH, Zhao QY, He MN, Jiang TA. Quantitative and noninvasive assessment of chronic liver diseases using two-dimensional shear wave elastography. World J Gastroenterol. 2018;24:957-970. [PMID: 29531460 DOI: 10.3748/wjg.v24.i9.957] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
669 Smiderle CA, Coral GP, DE Carli LA, Mattos AA, Mattos AZ, Tovo CV. PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS. Arq Gastroenterol 2021;58:139-44. [PMID: 34231659 DOI: 10.1590/S0004-2803.202100000-24] [Reference Citation Analysis]
670 Macut D, Tziomalos K, Božić-antić I, Bjekić-macut J, Katsikis I, Papadakis E, Andrić Z, Panidis D. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod 2016;31:1347-53. [DOI: 10.1093/humrep/dew076] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 8.6] [Reference Citation Analysis]
671 Lomonaco R, Bril F, Portillo-Sanchez P, Ortiz-Lopez C, Orsak B, Biernacki D, Lo M, Suman A, Weber MH, Cusi K. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. Diabetes Care. 2016;39:632-638. [PMID: 26861926 DOI: 10.2337/dc15-1876] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 12.2] [Reference Citation Analysis]
672 Yoshimura K, Okanoue T, Ebise H, Iwasaki T, Mizuno M, Shima T, Ichihara J, Yamazaki K. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology 2016;63:462-73. [PMID: